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(57) ABSTRACT 
A non-invasive method for analyzing the blood-brain barrier 
includes obtaining a Raman spectrum of a selected portion of 
the eye and monitoring the Raman spectrum to ascertain a 
change to the dynamics of the blood brain barrier. 
Also, non-invasive methods for determining the brain or 
blood level of an analyte of interest, such as glucose, drugs, 
alcohol, poisons, and the like, comprises: generating an exci- 
tation laser beam at a selected wavelength (e.g., at a wave- 
length of about 400 to 900 nanometers); focusing the excita- 
tion laser beam into the anterior chamber of an eye of the 
subject so that aqueous humor, vitreous humor, or one or 
more conjunctiva vessels in the eye is illuminated; detecting 
(preferably confocally detecting) a Raman spectrum from the 
illuminatedportion of the eye; and then determining the blood 
level or brain level (intracranial or cerebral spinal fluid level) 
of an analyte of interest for the subject from the Raman 
spectrum. In certain embodiments, the detecting step may be 
followed by the step of subtracting a confounding fluores- 
cence spectrum from the Raman spectrum to produce a dif- 
ference spectrum; and determining the blood level andor 
brain level of the analyte of interest for the subject from that 
difference spectrum, preferably using linear or nonlinear 
multivariate analysis such as partial least squares analysis. 
Apparatus for carrying out the foregoing methods are also 
disclosed. 
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FIG. 31B. 
In vivo Raman spectra of structures of the anterior chamber of a rabbit. Raman spectra of 
AH can clearly be distinguised from those of nearby cornea and lens. 
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The Raman spectra of 0.333M aqueous solutions of ethanol, acetaldehyde, and 
acetic acid each have similar Raman cross-sections. The spectrum of a mixture of the three 
metabolites is a sum of the individual spectra, demonstrating adherence to the Beer-Lambert law. 
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ASSESSING BLOOD BRAIN BARRIER 
DYNAMICS OR IDENTIFYING OR 
MEASURING SELECTED SUBSTANCES, 
INCLUDING ETHANOL OR TOXINS, IN A 
SUBJECT BY ANALYZING RAMAN 
SPECTRUM SIGNALS 
RELATED APPLICATIONS 
This application is a continuation-in-part of International 
Patent Application Serial No. PCTKJS102100649, filed Jan. 9, 
2002, which is a continuation-in-part of U.S. application Ser. 
No. 091756,897, filed Jan. 9,2001, now U.S. Pat. No. 6,574, 
501 which is a continuation-in-part of U.S. application Ser. 
No. 091690,113, filed Oct. 16,2000 now U.S. Pat. No. 6,424, 
850, which is a continuation of U.S. application Ser. No. 
091351,788,filedJul.12,1999,nowU.S.Pat.No.6,181,957, 
which claims the benefit ofpriority to U.S. Provisional Appli- 
cationNo. 601092,545, filed Jul. 13, 1998, the disclosures of 
which are hereby incorporated by reference as if restated in 
their entirety herein. 
The invention described herein was made in the perfor- 
mance of work under a NASA contract, and is subject to the 
provisions ofpublic Law 96-517 (35 USC 9 202) inwhichthe 
Contractor has elected to retain title. The United States Gov- 
ernment has certain rights to this invention. 
FIELD OF THE INVENTION 
The present invention concerns methods and apparatus for 
measuring or identifying the presence of selected substances 
in the body and/or assessing blood brain dynamics of a sub- 
ject via non-invasive spectrographic analysis of certain 
regions of the eye, such as the aqueous humor in the anterior 
chamber of the eye. 
BACKGROUND OF THE INVENTION 
Non-invasive measurement of physiological and foreign 
substances, including blood glucose, by optical spectroscopy 
techniques has remained an elusive target for at least two 
decades. Blood, tissue, and most excreted fluids contain 
numerous substances which confound many spectral signa- 
tures. On the other hand, the aqueous humor (AH), which fills 
the anterior chamber ofthe eye (between the lens and cornea), 
contains relatively few molecules capable of interfering with 
the spectroscopic detection of glucose. These are primarily 
lactate, ascorbate, and urea. This fact, along with its optically 
accessible location behind the cornea, makes the AH an 
attractive choice as a site on which to attempt non-invasive 
analysis of many substances present in a biological subject, 
including glucose. 
Pohjola (Acta Ophthalmologica Suppl. 88, 1-80 (1996)) 
showed that the ratio of aqueous glucose to plasma glucose in 
normal euglycemic individuals is related to age and ranges 
from 0.6 to 0.9. He further showed in seven humans with 
steady-state hyperglycemia that similar ratios applied. There 
is little, if any, data regarding the equilibration time of aque- 
ous humor glucose with changes in plasma glucose in 
humans. Some recent research suggests that the glucose con- 
tent of the AH compared with that in the capillary blood in 
man is about 0.75 regardless of the glycemic state of the 
person. See e.g., Schrader et al., The glucose content of the 
aqueous humour compared with capillary blood in man, 
Invest. Ophthalmol. Vis. Sci. (Suppl.) 44:404 (2000). 
Numerous investigators over the years have suggested that 
the ratio of aqueous glucose to plasma glucose in the nor- 
2 
moglycemic rabbit ranges from 0.42 to 1.01 (S. Pohjola, 
supra; D. Reddy andV. Kinsey, Arch. Ophthalmol. 63, 715- 
720 (1960); M. Reim et al., Ophthalmologica 154, 39-50 
(1967); W. March et al., Diabetes Care 5, 259 (1982)). It is 
5 uncertain whether this variability is normal or could be attrib- 
uted to differences in glucose measurement techniques, col- 
lection techniques, sample storage, and anesthesia. It is 
believed that the relationship of aqueous glucose to rising, or 
falling, plasma glucose has not been previously studied in 
Cot6 has reviewed the relative strengths and weaknesses of 
optical glucose sensing techniques (J. Clin. Engineering 22, 
253 (1997)). Raman spectroscopy is potentially attractive 
because it can distinguish glucose in water solutions contain- 
15 ing various levels of other optically active metabolites (S. 
Wang et al., Applied Optics 32,925 (1993)). Raman spectros- 
copy measures the shift in the wavelength of incident light as 
it is scattered by molecules. Any given molecule typically 
causes a characteristic shift in the spectrum of scattered light, 
20 which is dependent upon its intermolecular and intramolecu- 
lar bonds. This is in contradistinction to fluorescence, which 
is caused by changes in electron energy states, and does not 
shift relative to the wavelength of incident light. 
Wicksted et al, (Appl. Sectroscop. 49, 987 (1995)) suggest 
25 that the Raman signature for glucose can be identified in 
aqueous humor samples, and Goetz et al. (ZEEE Trans. 
Biomed. Eng. 42, 728 (1995)) have demonstrated that higher 
than physiologic levels of glucose can be measured with 
Raman spectroscopy in water solutions. J. Lambert et al. 
30 (LEOS Newsletter 12, 19-22 (1998)) suggest that measure- 
ment of glucose at physiologic levels is possible in water 
solutions containing other analytes normally found in the 
aqueous humor. In certain situations, when solutions contain- 
ing fluorescent substances are studied, however, the fluores- 
35 cence signal may overwhelm the relatively weak Raman- 
shifted signal. This is a potential problem if Raman 
spectroscopy is applied to certain regions in the eye, such as 
the conjunctiva or vitreous or aqueous humor (and/or depend- 
ing upon what the Raman signal is attempting to identify or 
U.S. Pat. No. 5,243,983 to Tarr et al. proposes a non- 
invasive blood glucose measurement system using stimulated 
Raman spectroscopy. Stimulated Raman spectroscopy can 
require the use of both a pump and a probe laser beam. In 
45 operation, the probe laser beam is used to measure the stimu- 
lated Raman light at a single wavelength after transmission 
across the anterior chamber of the eye. Commercially, this 
may be undesirable, since an optical component contacting 
the eye is used to direct the beam across the anterior chamber. 
50 In addition, use of a single wavelength may limit the ability to 
measure glucose at physiologic levels within tissue contain- 
ing many other Raman scattering chemicals. 
Others have also proposed various glucose measurement 
devices. For example, U.S. Pat. No. 5,433,197 to Stark sug- 
55 gests a non-invasive glucose measurement apparatus that 
employs broadband, infrared light stimulation. In addition, 
U.S. Pat. No. 5,553,617 to Barkenhagen proposes a non- 
invasive method for measuring body chemistry from the eye 
of a subject by measuring a spectral response such as a Raman 
60 scattering response. While the latter reference alleges that it 
may be used for medical applications (such as the determi- 
nation of sugar in diabetics), specific details on how this 
might be accurately carried out are not provided. Another 
example is found in U.S. Pat. No. 5,710,30 to Essenpreis, 
65 which proposes a method for measuring the concentration of 
glucose in a biological sample such as the eye (see FIG. 4 
therein) with interferometric measurement procedures. Still 
i o  rabbits. 
40 measurer), which can contain proteins that fluoresce. 
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another example is proposed in U.S. Pat. No. 5,666,956 to 
Buchert et al., wherein it is proposed that an instrument for the 
non-invasive measurement of a body analyte can be based on 
naturally emitted infrared radiation. 
In spite of the foregoing efforts, a commercially viable, 
non-invasive monitor which can successfully employ a non- 
invasive optical analysis of certain regions of the eye, includ- 
ing the aqueous humor of the eye, has not yet been developed. 
Difficulties in developing such a device include: (a) determin- 
ing reliable correlations ofthe typical millimolar quantities of 
selected substances or chemicals; (b) obtaining accurate mea- 
surements of selected substances; and (c) inhibiting damag- 
ing effects to the eye which may be caused by excessive 
exposure to light in an instrument that is used to generate the 
analysis signal spectrum in the AH. Accordingly, there is a 
continued need for improved systems, methods, and devices 
for the non-invasive in vivo analysis of foreign and natural 
physiologic substances in a biological subject via analysis of 
certain regions of the eye. 
SUMMARY OF THE INVENTION 
The present invention provides methods and systems for 
monitoring or evaluating the blood aqueous barrier and, thus, 
the blood brain barrier dynamics of the subject. The present 
invention also provides methods and systems which can 
detect the presence or absence of one or more selected sub- 
stances or analytes of interest in the body by optically ana- 
lyzing certain regions of the eye, including at least one of the 
AH, the vitreous humor (“VH’)), and one or more blood 
vessels in the conjunctiva. In certain embodiments, the analy- 
sis can provide information regarding the presence of andor 
quantify a detected substance in the body such as in the 
cerebral spinal or intracranial fluid of the subject (indirectly, 
through a correlation with the presence or quantification of 
the substance in the bloodvessel in the conjunctiva, or the AH 
or the vitreous humor). 
Embodiments of the invention can employ Raman spec- 
troscopy to non-invasively obtain, in vivo, at least one signa- 
ture spectroscopic signal to identify andor measure the level 
or concentration of a substance or substances of interest in the 
subject (either in the blood andor brain) based on the signal. 
In certain embodiments, the present invention can be used 
to monitor or evaluate the blood brain barrier dynamics, 
which may be intentionally altered (such as through the 
administration of chemicals or exposure to certain environ- 
mental conditions such as increased pressure) during such 
evaluation. By intentionally breaking down the blood brain 
barrier, medicines which are normally inhibited from cross- 
ing the barrier may be allowed to more readily cross and enter 
into the brain. To monitor such a change in the operation or 
dynamics of the blood brain barrier, non-specific markers can 
be introduced or injected into the subject. The non-specific 
marker is selected based on its molecular size andor its 
normal reluctance to cross the blood brain barrier. The blood 
brain barrier can then be intentionally altered (broken down 
or opened) so that the non-specific marker is able to cross 
therethrough. An optical reading of a selected region of the 
eye can be taken, and the present invention can assess whether 
the marker is present (either at all or in an increased amount 
over a pre-alteration state) in the blood aqueous barrier. Fur- 
ther, in some embodiments, the concentration ofthe marker in 
the eye can be determined (such as in the AH or vitreous 
humor) in the blood aqueous compartment. If the marker is 
identified as being present, this indicates that the blood brain 
barrier has been altered. Once the blood brain barrier is 
altered, a desired treatment regimen can be administered to 
4 
the subject (such as drug used for chemotherapy) to treat 
tumors or other conditions in the eyes or brain. In some 
embodiments, as an alternative to the use of non-specific 
markers, the present invention can monitor the presence or 
5 concentration of the treatment drug itself in the blood aque- 
ous compartment in the eye. Examples of suitable markers 
include large molecule natural and synthetic substances that 
do not normally cross the blood brain barrier, including, but 
not limited to, antibiotics including antifungal agents andor 
i o  erythromycin, and conjugated substances such as conjugated 
billirubin. 
Typically, the treatment drug is configured such that it is 
inhibited from crossing the blood brain barrier. Thus, in cer- 
tain applications, in order to deliver a sufficient quantity of the 
15 drug to the brain, the amount of drug, which is systemically 
delivered, can be undesirably toxic to the patient away from 
the targeted treatment region in the brain. The present inven- 
tion can now assess or assure either that the barrier is suffi- 
ciently altered to allow the drug to pass more efficiently 
2o therethrough andor quantify or assess that a sufficient 
amount of the treatment drug is getting into the brain so that 
the systemic amount can be more closely regulated and 
reduced. After the desired treatment (or dose) is indicated as 
delivered to the brain, the blood brain barrier can be restored 
such that it is substantially in its pre-altered state. The return 
25 to the pre-altered state can be confirmed by taking another 
optical reading to confirm that the marker is in a reduced 
concentration in the blood aqueous compartment in the eye. 
By identifying andor quantifying the amount of the non- 
specific marker present in the aqueous humor (and, thus in the 
30 blood aqueous barrier), an estimate or determination of the 
concentration in the brain can be established. Typically, the 
concentration in the blood aqueous humor can be presumed to 
be similar to that in the blood brain compartment. Further, the 
two concentrations can be correlated so that a quantitative 
35 value of the amount in the cerebral spinal or intracranial fluid 
can be determined based on that found in the blood aqueous 
compartment so that a titrated dose of the treatment drug in 
the brain may be able to be determined. The correlation rela- 
tionship or ratio may vary within certain population seg- 
40 ments. In certain embodiments, the correlation relationship 
can be determined based on data collected across a represen- 
tative population (by age, size, weight, gender, race, disease 
or physiological impairment or abnormality, or national ori- 
gin). Thus, the amount ofthe selected treatment drug actually 
45 getting into the brain can be correlated to the systemic dose 
delivered to the patient so that the dose or level in the spinal 
fluid is sufficiently high for treatment of the tumor or other 
condition but the systemic dose is sized to provide reduced 
toxicity to the subject (by avoiding administering unneces- 
50 sary quantities to the subject). 
In certain embodiments, the present invention can provide 
methods, similar to that discussed for intentionally altering 
the dynamics of the blood brain barrier, which use a non- 
specific marker with a new drug to evaluate the impact that a 
55 new drug or therapy regimen has on the blood brain barrier for 
safety or other considerations. 
In other embodiments, the optical detection of an analyte, 
agent, or drug itself, in certain regions of the eye, without the 
use of a marker, may be sufficient to indicate the drug’s 
In other embodiments, the environmental conditions sur- 
rounding the patient or subject, can be altered and the dynam- 
ics of the blood brain barrier monitored. For example, sub- 
jects which are exposed to different elevations, gravity 
65 conditions, or to increased intracranial pressure, may exhibit 
different or altered blood brain barrier characteristics, either 
transiently, or more chronically, than persons not so exposed. 
60 impact on the blood brain barrier. 
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These subjects may include astronauts, pilots, divers, trauma 
victims, and the like. Evaluating the blood brain barrier 
dynamics can identify whether larger molecules or pathogens 
are able to cross the blood brain barrier, which may, under 
normal circumstances, be inhibited or prevented from enter- 
ing the brain. In certain embodiments, the present invention 
can be used to assess which constituents in the blood cross 
into the intracranial fluid via the blood brain barrier. 
As generally described above, in one embodiment, a 
patient can undergo a treatment regimen to deliberately or 
intentionally alter the blood brain barrier dynamics so that an 
identified treatment agent(s) is allowed to cross the barrier. 
For example, an osmotic agent such as a drug (for example, 
MANNITOL) can be delivered to a subject being treated for 
cancer to force the blood brain barrier to open (preferably for 
a limited-time treatment window) to successfully allow a 
selected chemotherapeutic agent (such as a cytotoxic agent) 
to be able to more readily cross the blood brain barrier into the 
brain. Non-invasive monitoring of the tumor dose according 
to the present invention, can allow monitoring of the barrier 
dynamics and may, in some embodiments, be able to assess 
when an adequate, but not excessive, tumor dose is delivered 
to the brain. The blood brain barrier can be reestablished after 
the appropriate tumor dosing is delivered. This monitoring of 
the blood brain barrier dynamics during a treatment regimen 
may now inhibit or reduce systemic damage in the subject 
associated with the cytotoxic treatment. 
In other embodiments, the present invention provides sys- 
tems and methods for detecting the presence of a predeter- 
mined substance or identifying the presence of an unknown 
substance in the body of a subject. The substances which can 
be measured or identified are numerous and can be (a) natural 
physiologic analytes or chemicals, such as glucose, amino 
acids, peptides, antibodies, blood (typically using light out- 
side the red spectrum), andor (b) foreign substances such as 
medicaments, drugs, or poisons (whether legal or illegal, and 
whether prescription or over the counter). For example, the 
present invention can be used to assess the presence of tar- 
geted illegal substances, such as alcohol or illegal narcotics 
such as cocaine, pcp, marijuana, or to identify what toxin or 
poison a subject has injested out of a number of household or 
environmental toxins andor poisons such as herbicides, pes- 
ticides, household cleaning products, petroleum products or 
other common house hold chemicals including benzene, eth- 
ylene glycol. The methods and systems of the instant inven- 
tion may even be used to identify the presence of poisonous 
plants, insect toxins, and reptile or snake venom. The present 
invention may be configured to identify whether an unknown 
substance in a subject is one or more of toxinsiagents associ- 
ated with the most prevalent poison-related emergency room 
visits. For example, ethylene glycol, methanol, and acetami- 
nophen. 
In certain embodiments, the present invention can be used 
to quantify the amount of a substance in the subject. Typically 
this embodiment may be particularly suitable for those sub- 
stances ingested or existing in relatively large quantities or 
those present in sufficient quantity in the selected region of 
the eye so as to be detectable in vivo, or so that the substance 
or analyte is present in physiological levels (in the blood or 
blood aqueous compartment) of above about 0.001% or 
above about 0.01 -10 pmolars. In certain embodiments, the 
system and methods can assess low levels of analytes, such as 
between nano-micromolar levels, depending on the Raman 
active characteristics of the analyte of interest. For example, 
for certain substances having molecules that generate reso- 
nant Raman spectra and, the signal strength can be greatly 
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enhanced for certain excitation wavelengths that, in turn, may 
reduce the amount of the analyte that is detectable over non- 
resonant Raman spectra at that wavelength. 
In addition, in certain embodiments, the devices and meth- 
ods ofthe present invention may be used to detect increased or 
decreased levels of physiologic analytes such as caused by 
system impairments or reactions associated with dehydra- 
tion, allergic reactions, or physiologic analytes associated 
with bacterial infections such as spinal meningitis, or to iden- 
tify whether proteins or antibodies are present in elevated 
levels to identify a systemic response or a localized infection 
or disease in the eye or an immune system response, in the 
subject. Certain particular embodiments of the invention may 
also be used to treat the eye. 
In certain embodiments, the systems and methods of the 
present invention may be able to detect or identify toxins 
released or emitted from foods contaminated with food poi- 
soning bacteria such as E coli, salmonella (either invivo or in 
vitro). Further, in some embodiments, the methods and sys- 
tems of the present invent may be used to identify the pres- 
ence of mad cow disease by analyzing certain regions of the 
eye (either in vitro or in vivo) such as by obtaining a Raman 
spectrum of a desired region of the eye analyzing the spec- 
trum to detect the presence of small peptides or other markers 
associated with the disease. Other diseases may be able to be 
identified invivo by the presence of a systemic reaction (such 
as an increased constituent level of a natural physiologic 
substance) in the subject. It is anticipated that such a method 
may be potentially used to assess whether the subject has 
contracted Lyme disease associated with deer tick bites or 
Rocky Mountain spotted fever. 
In some embodiments, the invention can identify the pres- 
ence of one or a plurality of household or environmental 
poisons in the subject in a relatively fast “triage” assessment 
to allow clinicians to determine the appropriate treatment in a 
timely manner. This can be particularly important for pediat- 
ric applications where the substance ingested may be difficult 
to ascertain for young children, and a relatively quick identi- 
fication of a particular toxin or toxins ingested may allow 
more reliable or faster treatment decisions to be established. 
One embodiment of the invention is directed to an in vivo 
method for monitoring the blood brain barrier dynamics of a 
subject, comprising the step of monitoring the dynamics of 
the blood brain barrier by non-invasively obtaining the 
Raman spectrum of a selected region in the eye of the subject. 
The method may also include the step administering a non- 
specific marker to the subject selected for its normal reluc- 
tance to cross the blood brain barrier under the normal con- 
dition. The monitoring step can comprise detecting the 
presence of the non-specific marker in the selected region of 
the eye of the subject. 
In certain embodiments, the method can include the steps 
of altering the dynamics of the blood brain barrier of the 
subject from a normal condition; and administering a quantity 
of a selected therapeutic agent to a subject for treatment of 
condition in the brain or neurological system after the altering 
step. It can also include the step of substantially returning the 
blood brain barrier to its normal state after a sufficient quan- 
tity of the therapeutic agent has been delivered to the brain. 
Similarly, the monitoring step can be performed before the 
therapeutic drug is administered to the subject and subse- 
quently to confirm that the blood brain barrier is substantially 
returned to its normal condition. The method may also 
include the step of assessing the dose amount ofthe therapeu- 
tic agent delivered to the brain. 
Certain embodiments of the present invention are directed 
to an in vivo a non-invasive method for determining the level 
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of an analyte of interest in a biological subject. Raman spec- 
troscopy can be used to obtain the signature of the substance 
in the eye (such as in the AH, VH, or blood vessel in the 
conjunctiva) and, in some embodiments, to measure the con- 
centration of a natural physiologic or foreign substance, such 
as glucose and/or proteins, or drugs, alcohol, environmental 
or household toxins, in the subject. The method can include 
the steps of: (a) generating an excitation laser beam (e.g., at a 
wavelength of from about 400 to 900 nanometers); (b) focus- 
ing the excitation laser beam into the eye of the subject so that 
a selected region of the eye is illuminated; (c) detecting (pref- 
erably confocally detecting) a Raman spectrum from the illu- 
minatedregion ofthe eye; (d) comparing the Raman spectrum 
from the detecting step to predetermined spectrums corre- 
sponding to different analytes of different concentrations; and 
(e) identifying the presence of an analyte of interest based on 
the detecting and comparing steps. 
In some embodiments, an additional step (f) can be per- 
formed to determine the blood or brain level of an analyte of 
interest for the subject from the Raman spectrum. The blood 
or brain level may be indirectly computated based on the 
concentration or amount of the analyte in the blood aqueous 
compartment (or can be directly measured in the blood itself 
for the conjunctiva vessel measurement). For the indirect 
measurement, that value can be correlated (or adjustedcor- 
rected) to provide an assessment of the amount of the sub- 
stance in the cerebral spinal fluid or blood. The correlation 
may be such that the amount of the substance directly mea- 
sured in the AH is substantially similar to that in the cerebral 
spinal fluid. Alternatively, data correlating the relationship 
can be established and an empirical or statistical model estab- 
lished. 
Although not required, in some embodiments, the detect- 
ing step can be followed by the step of subtracting a con- 
founding fluorescence spectrum from the Raman spectrum to 
produce a difference spectrum; and determining the blood 
level of the analyte of interest for the subject from that dif- 
ference spectrum, preferably using linear or nonlinear multi- 
variate analysis such as partial least squares or artificial neural 
network algorithms. This technique may be particularly suit- 
able where fluorescence is problematic for optical measure- 
ments taken directly of the blood level (i.e., by focusing at the 
blood vessels in the conjunctiva or at the vitreous humor). 
In certain embodiments, a low energy excitation wave can 
be used to generate the Raman signal spectrum. “Low 
energy”, as used herein, means power which is on the order of 
about 10-400 mJ or less, and typically between about 70-330 
mJ. The energy exposure will depend on the power and pulse 
length of the excitation pulse. Longer wavelength pulses (i.e., 
above 700) may be used, typically with energy levels closer to 
the higher end of the scale, while lower wavelengths (400- 
700) may be used with lower energy exposure levels. In one 
embodiment, a wavelength of about 633 nm can be used for a 
pulse ofabout 5-10 seconds corresponding to about a 2-5 mW 
power exposure level (and between a 10-20 or 25-50 mJ 
energy exposure to the patient’s eye (or eyes)) for each mea- 
surement or monitoring signal obtained. In other embodi- 
ments, an optical excitation pulse may have a 785 nm wave- 
length, a pulse length of about 20 ms-5 s and a power rating of 
about 14-16 mW. In one embodiment, a 5 sec, 16 mW pulse 
can be used to obtain the in vivo reading of a cancer agent in 
the selected region of the eye (typically the AH). In yet other 
embodiments, for detecting and/or quantifying the presence 
of substances comprising particular molecules, an excitation 
wavelength can be selected that substantially corresponds to 
the absorption spectrum wavelength (for predetermined mol- 
8 
ecules that generate resonant Raman) with a reduced power 
requirement of between about 1-5 mW and an exposure time 
of about 10 seconds or less. 
In some embodiments, the excitation beam can be trans- 
5 mitted such that it presents a reduced energyidensity exposure 
rating to the tissue of the eye by shaping the beam to increase 
the cone angle or span of the excitation beam as it enters the 
eye to expose more of the area of the retina and reduce the 
energyiarea rating of the excitation pulse to provide improved 
i o  margins of safety (placing the energyiarea rating sufficiently 
below the threshold of damage). In other embodiments, the 
transmission path numerical aperture is substantially 
matched to the return path numerical aperture (of the spec- 
trometer). 
A second aspect of the present invention is an apparatus for 
the non-invasive in vivo determination of the blood level of an 
analyte of interest in a subject. The apparatus includes a laser 
source for generating an excitation laser beam (e.g., at a 
wavelength of from about 400 to 900 nanometers) and an 
20 optical system (e.g., a confocal optical system) operatively 
associated with the laser for focusing the excitation laser 
beam into a selected region of the eye, including one or more 
blood vessels in the conjunctiva of the eye, the vitreous 
humor, or the anterior chamber of an eye (or eyes) of the 
25 subject so that the aqueous humor in the desired region of the 
eye is sufficiently illuminated. The apparatus also includes a 
detector operatively associated with the optical system and 
configured to detect a Raman spectrum from the selected 
illuminated region of the eye and a processor with computer 
30 program code for identifying the presence of one or more 
selected substances or analytes of interest. The computer 
code may also include code for determining the in vivo level 
of the analyte of interest in the selected region of the eye and 
to establish an estimate or measure of the analyte in the blood 
35 or cerebral spinal fluid to be established based on a correlation 
thereto for the subject from the Raman spectrum. 
Focusing the optical analysis on the blood vessels in the 
conjunctiva can allow for a direct measurement of the sub- 
stance in the blood, while the measurements taken from other 
40 portions of the eye can be correlated to provide an estimate or 
quantification of the substance in the blood and/or in the 
cerebral spinal fluid (Le., indirect measurements). The corre- 
lation’s can be established based on empirical models or 
actual measurements taken in vitro or in vivo on a represen- 
45 tative animal or human population as is well known to those 
of skill in the art. 
In certain embodiments, the apparatus can be configured as 
a low energy unit to inhibit the exposure of the tissue during 
the operation of the apparatus. The excitation wavelength at 
50 the low power may be less than 700 nm, such as about 406 nm 
or 633 nm. 
Numerous additional features may be incorporated into the 
apparatus. The device may include a visual display screen for 
presenting visual indicia to the user, which can be individu- 
55 ally adjusted and focused to the particular visual acuity of the 
subject (similarto vision screening focusingprocedures). The 
apparatus may include a visual display screen for visually 
displaying the results of the test to the subject (such as 
through the same aperture or adjacent active matrix screen) as 
60 which the test is conducted. It may include a visual fixation 
target or device, also visible through the test aperture, which 
controls movement ofthe eye and simultaneously insures that 
focusing of the laser beam is properly directed into the ante- 
rior chamber of the eye. The processor may contain empirical 
65 models of actual testing experience to either determine the 
blood level or concentration of the analyte of interest or to 
identify the presence of selected substances. The apparatus 
15 
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may employ a laser of fixed wavelength, a tunable laser 
(which can sample a plurality of Raman scattered light (at 
different wavelengths) concurrently), a plurality of fixed 
wavelength lasers, or other light source means some ofwhich 
can include means for sliding the Raman spectrum passed a 
plurality of different wavelength detectors to obviate the need 
for a full grating based Raman spectrometer (by taking a 
plurality of samples). The apparatus may include a wireless or 
remote communication line operably associated with the pro- 
cessor for transmitting the blood level of the analyte of inter- 
est to a remote location (such as for emergency home calls to 
an ER room). 
Other devices may be particularly configured to detect the 
presence of a selected substance and thus, configured to 
detect the ensemble profile of the spectrum or a peak or peaks 
of interest. A compact, inexpensive device can include a fixed 
wavelength diode laser excitation source (configured to oper- 
ate so as to generate a resonant Raman spectrum for a mol- 
ecule of interest), and a filter, a lens, and detector. 
Another aspect of the present invention is an in vivo 
method for administering drug or chemical therapy to a sub- 
ject (such as for treatment of a cancerous tumor in the brain). 
The method includes the steps of: (a) administering a dose of 
a selected therapeutic agent to a subject; (b) altering the 
dynamics of the blood brain barrier from its normal state; (c) 
monitoring the dynamics of the blood brain barrier by non- 
invasively obtaining the Raman spectrum of a selected region 
in the eye (such as the vitreous or aqueous humor) and deter- 
mining the quantity ofthe agent therein. The method may also 
include one or more of (d) estimating the dose of the thera- 
peutic agent delivered to the brain (indirectly, based on the 
amount detected in the selected region of the eye) (e) repeat- 
ing said monitoring step a plurality oftimes during the admin- 
istering step; and (f) returning the blood brain barrier to its 
normal state after a sufficient quantity of agent has been 
delivered to the brain. 
In one embodiment, the altering step can be carried out by 
introducing a chemical to the subject to temporarily open the 
blood brain barrier to allow larger molecules to pass there- 
through. Further, the method can include the step of admin- 
istering anon-specific marker which is reluctant to or does not 
normally pass throughthe bloodbrainbarrier (i.e., is typically 
inhibited from passing therethrough). The optical analysis 
can monitor any increase (or the presence) of the non-specific 
marker in the selected region of the eye to confirm that the 
blood brain barrier dynamics has been altered. 
In another embodiment, the altering step may be carried 
out by increasing the intracranial pressure of the subject. 
Another aspect of the present invention is a method of 
non-invasively monitoring the blood brain barrier. The 
method comprises the steps of: (a) generating an excitation 
beam at a wavelength of from 400 to 900 nanometers; (b) 
focusing the excitation beam of said generating step into the 
anterior chamber of an eye of the subject so that aqueous 
humor in the anterior chamber is illuminated; (c) detecting a 
Raman spectrum corresponding to the illuminated aqueous 
humor; and (d) monitoring the AH to predict the behavior of 
the blood brain barrier dynamics during exposure to selected 
conditions based on the detecting step (based on the AH 
Raman spectrum analysis’ indication of the presence or con- 
centration of selected substances therein). It is anticipated 
that the correlation between the blood-aqueous and blood 
brain barrier is such that the presence andor concentration in 
one can be extrapolated to that in the other. 
Other embodiments focus the excitation beam such that it 
has an increased or wider cone angle to spread the light across 
more area of the retina. Still other embodiments are config- 
10 
ured to focus to one or more blood vessels on the conjunctiva 
or to focus deeper to the vitreous humor. 
In certain embodiments, the monitoring step can be used to 
assess whether the dynamics thereof alter sufficiently to allow 
5 selected analytes, which would normally be inhibited from 
traveling through the blood brain barrier, to pass into the 
intracranial spinal fluid through the blood brain barrier. In 
other embodiments, the monitoring step can be carried out 
when a person is under or exposed to extreme conditions such 
10 as when diving, flying, or mountain climbing, or when suf- 
fering from a traumatic head or brain injury, or high stress, 
and the like. 
The method can also include the steps of comparing the 
Raman spectrum from the detecting step to reference spec- 
l5 trums corresponding to at least one selected analyte of inter- 
est; and identifying the presence of the least one analyte of 
interest in the subject based on the detecting and comparing 
steps in the selected region of the eye. The method may also 
be able to estimate the dose or affirm the presence of the 
Yet another aspect of the present invention is a method for 
identifying an alteration in the blood brain barrier of a bio- 
logical subject, comprising the steps of: (a) non-invasively 
obtaining a first in vivo Raman spectrum of the aqueous 
25 humor of the subject; (b) non-invasively obtaining a second in 
vivo Raman spectrum of the aqueous humor of the subject; 
and (c) identifying an alteration in the blood brain barrier by 
comparing the first and second Raman spectrums. 
An additional aspect of the present invention is a method 
for identifying an alteration in the blood brain barrier of a 
biological subject, comprising the steps of: (a) non-invasively 
obtaining a first in vivo Raman spectrum of the aqueous 
humor ofthe subject; (b) obtaining a reference spectrum of an 
in vitro sample representing the aqueous humor and compris- 
ing at least one selected analyte; and (c) comparing the invivo 
Raman spectrum to the reference spectrum to identify an 
abnormality in the blood brain barrier by detecting the pres- 
ence of at least one selected analyte in the AH thereby indi- 
The at least one selected analyte can be one which typically 
does not cross the blood brain barrier so that its presence is 
indicative of an abnormality or impairment or successful 
intentional alteration of the blood brain barrier dynamics. 
Each of the embodiments of the invention may include 
computer program products and computational and look-up 
table associated therewith to identify the presence of the 
selected substance or substances of interest (andor calculate 
the amount or concentration thereof) and to operate or control 
50 (regulate) the power of the excitation pulse emitted from the 
laser, and the illumination and detection of the scattered light. 
For example, in certain embodiments, the present invention 
can include a computer program product for determining the 
identity of an unknown substance in a subject. The product 
55 can comprise computer-readable program code comprising: 
(a) computer readable program code for defining at least one 
signature reference spectrum for at least one selected sub- 
stance of interest; (b) computer readable program code for 
analyzing an invivo obtained Raman spectrum ofthe aqueous 
60 humor of the subject; and (c) computer readable program 
code for based evaluating whether the in vivo Raman spec- 
trum corresponds to at least one of the at lest one signature 
reference spectrums by comparing selected characteristics 
between the reference spectrum and the in vivo spectrum. 
In various embodiments, the computer readable program 
code for defining the different reference spectrums can be for 
a particular one or a plurality of different selected substances. 
2o analyte in the subject’s cerebral spinal fluid. 
3o 
35 . 
4o cating its presence in the intracranial fluid of the subject. 
45 
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Examples of the selected substance(s) include, but are not 
limited to: drugs or analytes of interest including, but not 
limited to, alcohol, a substance banned for athletes in com- 
petition, a plurality of illegal narcotic substances, a plurality 
of household products or common poisons for humans or 
animals which are potentially poisonous to a subject when 
ingested, a chemotherapy agent, an antifungal agent, antibi- 
otics, naturally occurring in vivo analytes, and the like. A 
response curve that is substantially identical to the measured 
Raman spectra of the mixed sample in the eye. 
The obtained Raman spectrum data may be normalized by 
dividing by the area of the spectrum associated with a hydro- 
5 gen-bonding region in the 400-600 cm-' range of the spec- 
trum. The transmitting step may be carried out by confocally 
delivering the excitation beam to the aqueous humor of the 
eye of the subject. 
master look-up reference data base providing Raman spec- The present invention will now be described further and 
trum data for one or a large quantity of different poisons or i o  includes other features and analytes that can be included in 
substances can be generated and stored at a central database 
or at local or regional offices, clinics or the like. The computer 
program can include means for remotely accessing the data 
such as via the use of an intranet or internet. 
The wavelength can be between about 400 nm-900 nm. 15 FIG. 1 is a graph which illustrates the broad spectrum of 
The selected analyte can be a chemotherapeutic agent, an water in the aqueous humor, which, in some situations, can 
antifungal agent, or other analyte ofinterest. Themethodmay obscure the underlying peaks of interest in the Raman spec- 
also include monitoring at least one peak of interest in the trum. The raw spectrum of rabbit aqueous humor is shown 
detected Raman spectrum associated with a carbon-carbon taken at 2 slightly different wavelengths (top). The difference 
bond and/or a double carbon bond associated with the chemi- 20 spectrum (bottom) achieved by subtracting 1 raw spectrum 
cal structure of the selected analyte. from the other reveals a resultant bipolar Raman signature. 
Still other embodiments are directed to methods ofmoni- Linear and/or nonlinear multivariate analysis can then be 
toring ethanol and/or its constituents in a subject using applied. 
Raman spectroscopy. The methods include: (a) obtaining a FIG. 2 is a graph plotting Raman predicted glucose as a 
plurality of reference Raman spectra of varying concentra- 25 function of actual glucose concentration. The glucose con- 
tions of ethanol and/or its metabolites; (b) transmitting an centration in aqueous humor from 16 rabbits was estimated 
excitation beam at a wavelength of from 400 to 900 nanom- with Raman spectroscopy and compared to the actual glucose 
eters to an eye of a subject; (c) obtaining a Raman spectrum of concentration measured with a commercial glucometer. The 
ethanol and/or its metabolites in the eye of the subject; (d) graph shows the Ramanpredictedglucose concentration after 
comparing the Raman spectrum from said obtaining step to at 30 subtracting fluorescence and applying a linear partial least 
least one of the reference spectra; and (e) determining the square algorithm followed by nonlinear back propagation 
presence of and/or the concentration of the ethanol and/or its with an artificial neural network. This resulted in a high 
metabolites in the subject based on said obtaining and com- degree of correlation (r2=0.9X) of predicted with actual glu- 
paring steps. cose concentration. Applying the partial least squares algo- 
the concentration of ethanol and metabolites acetaldehyde FIG. 3 is a graph plotting blood glucose as a function of 
and acetic acid based on the obtaining and comparing steps. time. Blood glucose steadily rises at variable rates in rabbits 
The method can also include obtaining biometric data ofthe after administration of xylazine anesthesia. One animal (rab- 
eye ofthe subject to confirm the identity ofthe subject proxi- bit D, filled diamonds) had little change in blood glucose for 
mate in time to the transmitting and obtaining steps. In par- 40 unknown reasons. 
ticular embodiments, the method can be carried out by sub- FIG. 4 is a graph plotting aqueous humor glucose as a 
tracting spectral contributions from predetermined function of blood glucose. Best-fit second-order polynomial 
constituents of the aqueous humor from the obtained Raman curves demonstrate the relationship between aqueous humor 
spectrum using data from an a priori baseline Raman spec- glucose and plasma glucose while plasma glucose is rising in 
trum of the aqueous humor without ethanol and ethanol 45 9 animals. Aqueous glucose measiirements from the first 
metabolites. The determining step can be capable of deter- paracentesis of an eye correlate well with simultaneous 
mining in vivo ethanol vales of between about 5-500 mgidL. plasma glucose (dark curve). When plasma glucose exceeds 
In certain embodiments, the excitation beam has a wave- 200 mgidL the relationship is nearly linear (dashed line). 
length between about 400 to 900 nanometers, wherein the Aqueous humor glucose exceeds plasma glucose when 
obtained Raman spectrum includes at least a portion of the 50 plasma glucose is less than 200 mgidL. The relationship of 
spectrum in the range of about 700-1700 cm-' and the deter- aqueous humor glucose with plasma glucose is different 
mining step include selectively excluding regions ofthe spec- when the aqueous humor sample is obtained as a second 
tra ina 700-1700 cm-' response regionin the Ramanresponse paracentesis (light curve) suggesting that the initial paracen- 
signal at which spectral shifts can occur at increased coiiceii- tesis disrupts normal glucose homeostasis. 
trations of ethanol. FIG. 5 schematically illustrates a first embodiment of an 
In particular embodiments, the method includes providing apparatus of the invention. 
a calibration model that analyzes a complex signal of mixed FIG. 6 schematically illustrates a second embodiment of an 
constituents for a plurality of separate constituent spectra apparatus of the invention. 
comprising at least ethanol, acetaldehyde and acetate. FIG. 7u schematically illustrates the method of sliding 
The calibrationmodel can employ partial least squares and 60 Raman spectra features through a particular detector window 
be configured so that the mathematical addition of the spectra 
of the separate constituent spectra results in a Raman FIG. 7b schematically illustrates an apparatus of the inven- 
response curve that is substantially identical to the measured 
Raman spectra of the mixed sample in the eye. In other FIG. 8 illustrates a visual fixation display that can be uti- 
embodiments, the calibrationmodel can employ hybridlinear 65 lized in an apparatus of the invention. 
analysis and be configured so that the mathematical addition FIG. 9 illustrates a visible readout display that can be 
of the spectra of the separate constituents results in a Raman 
the methods and apparatus described herein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In certain embodiments, the determining step determines 35 rithm alone resulted in lesser correlation (?=0.90). 
55 
by changing excitation frequency. 
tion that utilizes the method illustrated in FIG. 7u. 
utilized in an apparatus of the invention. 
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FIG. 10a is a schematic illustration of one embodiment of 
a light generation or light pulse system according to the 
present invention. 
FIG. 10b is a schematic illustration of one embodiment of 
a detection system according to the present invention. 
FIG. 1Oc is a schematic of one embodiment of a system 
with a closed loop feedback control system according to the 
present invention. 
FIG. 10d is a schematic of an alternate closed loop feed- 
back system according to embodiments of the present inven- 
tion. 
FIG. 11 is a block diagram of a method for determining the 
presence or the blood level concentration of a selectedanalyte 
according to certain embodiments of the present invention. 
FIG. 12 is a block diagram of a method for identifying the 
presence of at least one selected substance ina selectedregion 
of the eye of a subject to evaluate the quantity of same in the 
cerebral spinal or intracranial fluid (it being assumed that the 
mechanics of the blood aqueous barrier can be representative 
to the blood brain barrier, the same having passed through the 
blood brain barrier) according to certain embodiments of the 
present invention. 
FIG. 13 is a block diagram of a method for monitoring or 
treating a patient by administering a therapeutic agent during 
a chemotherapy session patient according to embodiments of 
the present invention. 
FIG. 14 is a block diagram of a method of monitoring the 
blood brain barrier dynamics of a subject during exposure to 
selected conditions according to embodiments of the present 
invention. 
FIG. 15 is a block diagram of a method for detecting an 
alteration of the function of the blood brain barrier according 
to certain embodiments of the present invention. 
FIG. 16 is a block diagram of a method for identifying an 
abnormality in the blood brain barrier of a subject according 
to embodiments of the present invention. 
FIG. 17 is a flow chart of a method according to one 
embodiment of the present invention. 
FIG. 18 is a schematic illustration of an apparatus config- 
ured to illuminate and obtain the Raman spectrum from the 
vitreous humor of the eye according to embodiments of the 
invention. 
FIG. 19 is a schematic illustration of an apparatus config- 
ured to illuminate and obtain the Raman spectrum of one or 
more blood vessels in the conjunctiva of the eye according to 
embodiments of the invention. 
FIGS. 20A-20C illustrate optical power density calcula- 
tions performed using a canonical model of the adult eye of a 
human. FIG. 20A is a model of the human eye. FIG. 20B is a 
schematic of a portion of the eye illustrating the angles an 
equations associated with power density. FIG. 20C is a graph 
of the power for exposed retinal area and the power density 
(assuming a 30 mW input) are shown as a function of the 
angle of incidence. 
FIGS. 21A-21C are graphs of the Raman spectrum of 
artificial and actual aqueous humor samples. FIG. 21A cor- 
responds to an ensemble spectrum of artificial aqueous humor 
samples in a model (artificial or test) anterior chamber. FIG. 
21B corresponds to an in vitro ensemble spectrum of actual 
aqueous humor in a model anterior chamber. FIG. 21C cor- 
responds to in vivo ensemble spectrum of aqueous humor. 
FIG. 22A is a drawing of the chemical structure of a che- 
motherapeutic agent known as fenretinide. FIG. 22B illus- 
trates the agent in ethanol in different concentrations (shown 
in decreasing concentration from left to right) of 100 pM 
(micro-molars), 10 pM, 1 pM, and 0.1 pM. 
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FIG. 23 is a graph of the absorption spectrum (absorption 
versus wavelength) of a solution of 10 pM of fenretinide 
illustrating the peak at 365 nm. 
FIG. 24 is graph of the Raman spectrum of intensity verses 
5 wavelength shift of a non-resonant Raman spectroscopy (us- 
ing an excitation wavelength of 785 nm) of fenretinide (dis- 
solved in ethanol). There are two distinct lines, one for etha- 
nol and one for fenretinide that shows key peaks of fenretinide 
as distinct from those of ethanol. 
FIG. 25A is a graph of the absorption spectrum (absorption 
versus wavelength) of a solution of 10 mM of fenretinide. 
FIG. 25A is inset within FIG. 25B. 
FIG. 25B is a graph of pre-resonant spectra (excitation 
wavelengths above the resonant wavelength) of a 10 mM 
l5 fenretinide corresponding to the substance with the absorp- 
tion spectrum shown in FIG. 25A. 
FIG. 26 is a graph of intensity versus wavelength shift of 
the resonant Raman (RR) spectra of fenretinide at three dif- 
ferent concentrations (mixed in ETOH), 10.0 pM, 1 .O pM, 
2o and 0.1 pM. The peaks from the solvent (S), ethanol, are 
diminished at the higher fenretinide concentrations due to the 
absorption of excitation light by the fenretinide itself. 
FIG. 27 is a drawing of the chemical conjugated structure 
FIG. 28 is a graph of the absorption spectrum of amphot- 
ericin B. 
FIG. 29 is a graph of the RR spectrum of (generated at an 
excitation wavelength of 406.7 nm) of amphotericin at three 
30 different concentrations (mixed in MeOH), 5.0 pgiml, 0.5 
pglml, and 0.05 pgiml. 
FIG. 30 is a schematic of a compact portable detector 
suitable for detecting the presence of a particular substance 
according to embodiments of the present invention. 
FIGS. 31A and 31B are graphs of intensity (arbitrary units) 
versus wave number of Raman spectrums. FIG. 31A is a 
graph of Raman spectra of an artificial aqueous humor and 
components of a physical model of the anterior chamber 
collectedusing confocal optics. FIG. 31B is a graphofRaman 
40 spectra of structures of the anterior chamber of a rabbit. The 
Raman spectra ofAH can be clearly distinguished from those 
of nearby cornea and lens. 
FIG. 32 is a graph of amplitude (arbitrary units) versus 
wave number of normalized Raman spectra of various levels 
45 of ethanol in artificial aqueous humor according to embodi- 
ments of the present invention. 
FIG. 33 is a graph of PLS-measured ethanol concentration 
versus actual ethanol concentration in aqueous solution 
according to embodiments of the present invention. 
FIG. 34 is a graph of the Raman spectra for 0.333 M 
aqueous solutions of ethanol, acetaldehyde, acetic acid, and 
mixed metabolites according to embodiments of the present 
invention. 
FIG. 35 is a block diagram of a computer program module 
and/or a data processing system according to embodiments of 
the present invention. 
10 
25 of amphotericin, an exemplary antifungal agent. 
35 
50 
55  
DESCRIPTION OF EMBODIMENTS OF THE 
60 INVENTION 
The present invention will now be described more fully 
hereinafter with reference to the accompanying figures, in 
which embodiments of the invention are shown. This inven- 
65 tion may, however, be embodied in many different forms and 
should not be construed as limited to the embodiments set 
forth herein. Like numbers refer to like elements throughout. 
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In the figures, layers, components, or features may be exag- ins andor poisons such as herbicides, pesticides, household 
gerated for clarity and broken lines indicate optional features cleaning products, petroleum products, therapeutic agents 
or operations unless described otherwise. such as chemotherapeutic agents, antifungal or other antibi- 
The term “glucose” as used herein preferably refers to otic agents or other chemicals. 
D-glucose. The term “subject” as used herein refers to both 5 In certain embodiments, the present invention may be par- 
human subjects and animal subjects having circulatory sys- ticularly suitable for identifying the presence or amount of 
tems including domestic large and small animals such as substances, which present in the selected region of the eye in 
dogs, cats, rabbits, horses, cows, pigs, and the like. Animal sufficient quantities to allow Raman based detection. For 
subjects may be used in the present invention for veterinary or example, in certain embodiments, the present invention may 
pharmaceutical drug study purposes. The present invention i o  be able to detect a substance that is present in an amount of at 
may be particularly suitable for human subjects. The optical least about 0.01-10 pmolars. In other embodiments, the 
analysis may be performed on selected regions of the eye, present invention can detect a substance that is present in at 
including the blood vessels in the conjunctiva (Le., one or least about 1-100 or 10-100 pmolars. The lower quantities 
more of the conjunctiva blood vessels located on the surface may be more reliably detectable if the substance is a Raman 
of the eye), the vitreous humor (the “VH’) or the aqueous 15 active molecule with enhanced signal strength obtained by 
humor (the “AH’). using an excitation wavelength that approaches the substance 
In certain embodiments, the present invention is concerned or molecule of interests absorption spectrum or RR excitation 
with the determination of (a) the blood levels or (b) the brain wavelength. In some embodiments, the targeted analyte may 
fluid level, meaning the intracranial or cerebral spinal fluid be present in the selected or targeted region of the eye in an 
levels, of selected substances or analytes of interest such as 20 amount of at least about 1 milli-molar or in a physiological 
may be predicted by the presence andor concentration of the concentration level of about at least 0.001%. The present 
substance or analyte in the selected region of the eye of a invention may also be able to identify the presence of, or a 
subject (typically, the AH or the conjuctiva vessel(s)). physiologic reaction to, substances associated with poison- 
In certain embodiments, the present invention recognizes ous plants, insect or arachnid poison, and reptile or snake 
that the mechanics of the blood aqueous barrier and the blood 25 venom, in the subject. 
brain barrier are substantially the same such that, if the sub- In addition, in certain embodiments, the devices and meth- 
stance of analyte passes through the blood aqueous barrier, it ods of the present invention may be used (to analyze either in 
can be presumed to also pass through the blood brain barrier. vitro or in vivo) to detect increased or decreased levels of 
The correlation of the amount that passes through the blood physiologic analytes in the blood or to detect certain disease 
brain barrier may be substantially equivalent to that detected 30 processes of known conditions andor to treat conditions of 
in the eye or may be at a lesser or greater concentration. the eye. For example, by identifying increased or decreased 
However, the blood concentration of other Raman-active levels of certain substances in the body or the presence in the 
molecules, analytes, or substances which do not typically subject of certain peptides or toxins associated with a particu- 
pass through the blood brain barrier may also be determined lar condition, such as those caused by system impairments or 
by these techniques. Similarly, the amount or presence of the 35 reactions associated with dehydration, allergic reactions, tox- 
selected substance or molecule, etc., in the eye itself can be ins from bacterial infections such as spinal meningitis, or 
determined by these techniques (such as to treat localized in elevated or decreased levels of antibodies to identify an 
the eye or non-systemic diseases such as cancers of the eye). immune system response, or even hormones evoked in 
As used herein, the term “analyte” is used interchangeably response to a pregnancy. 
with “substance” to identify a selected target chemical, mol- 40 In certain embodiments, the methods and devices of the 
ecule or molecules, either in its blood-absorbed or partially present invention can be configured to (a) identify the pres- 
absorbed, uptaken, or constituent form, or in an ex vivo for- ence of andor (b) quantitatively estimate or determine the 
mulation, where applicable. As such, the substance or analyte blood andor cerebral spinal or intracranial concentration 
can include a chemical compound or composition, whether level of one or more selected substances in the subject. The 
synthetic or natural, as well as a constituent thereof or mol- 45 quantitative assessment can include determining how much 
ecule of interest. In some embodiments, the analyte or sub- of the selected substance is crossing the blood brain barrier 
stance can be one that is emitted by the body (sometimes in an (based on a correlation to the amount present in the selected 
elevated amount) in response to a disease or physiologic region of the eye, typically the AH). In other embodiments, 
reaction to a product or toxin and may also be a byproduct of the methods and devices of the invention can be used to 
the body’s reaction to a substance. As such, as noted in the 50 dynamically monitor changes in the operation of the blood 
summary of the invention above, the substances which can be brain barrier (which may be altered intentionally for some 
measured or identified according to the present invention are embodiments of the invention). 
numerous and can include (a) natural physiologic substances, In any event, generally stated, in operation, a laser excita- 
analytes or chemicals, such as glucose, amino acids, peptides, tion light signal is focused to and transmitted into a selected 
blood, or other components of or in blood, or in the eye andor 55 region in the eye. Typically, this will be the AH, but, in some 
(b) foreign or synthetic or artificial substances such as medi- embodiments, can also include either the blood vessel(s) in 
caments, drugs, or poisons (whether legal or illegal, and the conjunctiva or the vitreous humor. Illumination of the 
whether prescription or over the counter) which may be blood vessel(s) in the conjunctiva ofthe eye will not require as 
present in the subject. For example, the present invention can great a penetration depth as either the AH or the vitreous 
be used to: (a) identify or assess the presence (or absence) of 60 humor, while the vitreous humor will require the excitation 
andor the blood level or concentration of or (b) the movement light pulse to have an increased penetration depth over that of 
through or alteration of the blood-brain barrier of a selected or the AH and the conjunctiva to reach the vitreous humor in the 
desired substance. The substances include lactate, urea, ben- eye. 
zene, ascorbate alcohol, ethanol, methanol, ethylene glycol, In any event, after the selected region of the eye is illumi- 
steroids, nicotine, or illegal narcotics such as cocaine, other 65 nated, a corresponding Raman spectroscopic signal is 
opiate-based drugs, or prevalent or pervasive designer drugs, obtained. Each selected substance can generate a “signature” 
or metabolites, or household, organic, or environmental tox- spectrographic signal with different signature peaks at differ- 
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ent frequencies. Higher concentrations will yield stronger 
signals. The subject’s spectroscopic signal can then be digi- 
tally compared to a plurality of reference signals stored in 
computer memory. The reference signals correspond to one 
or more selected substances which can be predetermined 
from an in vitro analysis of the substance as it exists in a 
corresponding sample. For example, for the AH measure- 
ment, a representative eye AH can be a representative target 
phantom such as in artificial AH’S, or test vials with known 
concentrations of the substance in a known solvent, such as a 
water based or saline solution. 
In certain embodiments, the actual signal of the subject can 
then be compared to the stored “signature” profiles or signals 
of Raman data corresponding to predetermined substances or 
analytes to identify the presence of one or a plurality of the 
selected substances andor to estimate or quantitatively deter- 
mine the concentration of that substance(s) in the subject. 
Thus, the present inventionis able to assess, non-invasively, at 
physiologic levels (typically in the millimolar range, but the 
levels can also be in the micromolar range for certain sub- 
stances), the presence of selected substances in the body of 
the subject. In other embodiments, a relative assessment (two 
or more measurements of the subject analyzed for differences 
or changes) may be performed, alone, or with the use of base 
or reference spectra. The relative assessment can include 
obtaining at least two different Raman spectrum signals of the 
subject, over time, and comparing any shift in peaks, and, 
thus, physiological changes, in the subject at particular fre- 
quencies. 
As shown in FIG. 5, in one embodiment of the present 
invention, the system 5 can be described has having a light 
(excitation or illumination) signal generation portion 8 and a 
detection portion 9 (FIG. lob) with a laser 10 and an optical 
system 15x, along with a fixation target 25. The optical sys- 
tem 15x can be broken into an input portion 15xi (relays the 
light to the subject’s eye) and an output portion 15x0 (relays 
thereflectedlight fromthe subject).As showninFIG. loa, the 
light signal generation portion 8 includes the laser 10, a signal 
processor 35s, the input optical system 15xi which is config- 
ured to direct the light signal into a selected region in the eye 
12 of the subject (whether the conjunctiva vessel(s), the AH, 
or the vitreous humor). The light generation portion 8 shown 
also includes a fixation target 25 used to help focus the sub- 
ject’s eye to the light transmission path. The target 25 may be 
configured to extend adjacently above, below or about the 
perimeter of a light exitientrance aperture, preferably proxi- 
mate to the aperture to allow the eye to focus directly at or into 
the aperture during operation or data acquisition. 
As shown in FIG. lob, the system 5 also includes the 
detection portion 9 which receives the light as it exits the 
selected region of the eye and detects the Raman spectrum 
associated therewith. The detection portion 9 can include the 
output optical system 15x0 (which may share some of the 
optical components used in the input optical system 15xi), 
and a spectrometer 32s with a detector 32, and a signal pro- 
cessor 35s. The signal processor 35s is typically the same in 
the transmission and detection portions 8, 9 of the system 5. 
A schematic diagram of one embodiment of the system 5 is 
shown in FIG. 5. In certain embodiments, in operation, a 
tunable, narrow-band laser beam from laser 10 is focused into 
the anterior chamber 11 of the eye 12 through an objective or 
ocular lens 13 via lens 15 and filter 16, beam splitter 17, and 
filter 20. In certain embodiments, a non-fluorescing objective 
lens with suitable numerical aperture (e.g. 0.2-0.5) can be 
used such that Raman scattering from the selected region (Le., 
the aqueous humor) is maximized while scattering from adja- 
cent structures (e.g., lens, cornea, and iris) is reduced. The 
18 
objective lens can be configured with respect to the eye so that 
it has adequate working distance to permit focusing of the 
laser into the selected region of the eye (for the AH, the 
middle of the anterior chamber of the eye) without direct 
5 contact with or touching of the cornea. An integrated fixation 
target projected from display screen 25 can be projected via 
lens 26 through the same objective lens as the laser, but is 
focused on the retina of the eye. Focusing this fixation target 
on the retina simultaneously can control direction and focus- 
i o  ing of the laser light into the desired region of the eye (such as, 
in some embodiments, to the anterior chamber and the AH). 
As shown in FIG. 5, in certain embodiments, the light 
collected by the objective lens is directed through holo- 
graphic notch filters 20,21 to remove the undesired portion of 
15 the reflected scattered light, such as the Raleigh scattered 
light. The Raman scattered light passes through these filters 
with minimal attenuation and is focused through a confocal 
pinhole aperture 22 by lenses 23, 24. The pinhole and the 
focal point in the eye are confocal such that light from adja- 
20 cent structures in the eye can be filtered at this aperture. The 
pinhole 22 also serves as the entrance aperture to the spec- 
trometer. The spectrometer shown is an imaging spectrograph 
with a grating 30, lens 31 and a CCD detector array 32. 
A signal processor 35s, or controller which can be provided 
25 in a computer 35, controls the laser 10, the fixation target and 
readout display 25, and receives data from the CCD detector 
32. The architecture of the spectrometer shown in the figures 
is merely one example of devices that are suitable for this 
application. Many types of spectrographs can be utilized 
30 including Fourier transform spectrographs, spectrographs 
using liquid crystal tunable filters or other tunable elements. 
Information can be transmitted to a remote source such as a 
computer, database, remote physician or the like via modem 
or other connection through a suitable communication link 36 
via a wireless link or a computer network such including an 
intranet or a global computer network link such as an internet 
link (such as the world wide web), etc. 
In certain embodiments, the CCD detector 32 in the spec- 
trometer is of a red-shifted, back-thinned, thick epitaxial 
design such that its sensitivity is optimal in the 700-1100 
40 nanometer spectral region. Other types of suitably sensitive 
detectors and spectral ranges may be suitable as well. 
As noted above, a signal processor 32s such as a digital 
signal processor in a general purpose or special purpose com- 
puter processes the output of the detector 32. The signal 
processor or computer or other controller can control the laser 
beam frequency and the power or intensity of the laser pulse 
from the laser source 10. 
In some embodiments, the signal processor 32s, computer, 
or controller can switch the frequency of the laser to permit 
50 subtraction of fluorescence as described previously. The sig- 
nal processor or computer can also direct information to a 
digital display imaged onto the retina. The patient can then 
read the results of the analysis on this display. For certain 
embodiments, the results can be displayed on the exterior of 
55 the device so that a clinician or police officer (the latter being 
particularly directed for narcotics or blood alcohol evalua- 
tions) can easily read same. Further, the data or results can be 
date and time coded and digitally stored and printed as a 
medical or police record. 
As shown in FIG. 6, fibers 40,41 may be used to deliver the 
laser beam and collect the Raman scattered light. In certain 
embodiments, the confocal aperture is a circular aperture 42 
placed on the end of a multimode fiber. As with the pinhole 
aperture shown in FIG. 5, the end of the fiber can be placed so 
65 that it is confocal with the objective lens’ focal point in the 
anterior chamber of the eye. A single mode fiber can be used 
to direct the laser beam into the anterior chamber of the eye. 
35 . 
45 
60 
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This single mode fiber can help facilitate a diffraction limited or user during operation to facilitate focusing of the excitation 
spot size at the focal point of the objective. light into the anterior chamber and maintain stability of the 
A fiber delivery and collection system like that depicted in eye (SO that it is Properly aligned With the eye ofthe subject). 
FIG. 6 can be connected to alternative detection systems, one In the admdiment of FIGS. 5-7, a display Screen such as a 
of which is shown in FIGS. 7a-b. This alternative detection 5 liquid crystal display is employed. As dmwn in FIG. 8, a 
system can allow for subtraction ofthe fluorescence spectrum blinking fixation target in the form of an hourglass 70 can be 
as well as selected sampling of the frequencies most impor- displayed, focused on the retina, during acquisition of the 
tant for calculation of glucose concentration. Such an alter- spectra by the apparatus. Other fixation target forms can also 
native detection system may decrease the size and cost of the be used such as text, letters, numbers, Or 0 t h  recognizable 
instrument. The system depicted in FIG. 7 uses one or more 10 shapes Or objects. This can help optimize the Raman signal 
fixed frequency or tunable lasers to illuminate the aqueous from the aqueous humor and reduce light exposure to other 
humor of the eye using the optical delivery system shown in Structures ofthe eye. The fixation target can be active during 
FIG. 6. the time that the laser beam is active and illuminating the 
FIG. 7a illustrates that each spectral feature 50a, 50b, 50c subject’s eye. 
ofthe Raman scattered light is related to the excitation wave- 15 AS shown in FIG. 9, in some embodiments, a visible indi- 
length by a fixed offset, usually expressed in wavenumbers. cation ofthe results ofthe test in the form of alphanumeric 
Changing the excitation wavelength causes the Raman spec- indicia 71 (or other suitable form, such as a graphical display) 
tra to shift in wavelength, as depicted by the different feature can be displayed on the Same Screen immediately after the 
or portion ofthe signal, captured in detector range window A, acquisition step (or to aremote or externally visible screen for 
51 (a relatively narrow band of the signal such as about 10 20 other embodiments). The indicia of FIG. 9 provides a readout 
nm) based on Raman spectra 52 for excitation frequency L,, for all ofthe Principal kman-active compounds ofthe aque- 
as compared to Raman spectra 53 for excitation frequency ous humor, but the display can be of a targeted Compound of 
b.2 interest (filtered from the overall spectra) corresponding to 
apparatus that takes advantage ofthe foregoing is sche- one or more, of a desired concentration level of a selected 
matically illustrated in FIG. 7b. Like components to FIGS. 5 25 substance (such as 
and 6 are assigned like numbers, Laser drivers and/or tuning In some embodiments, a motion sensor can be incorporated 
electronics 60 are operatively associated with a tunable laser into the device SO that the test Can be aborted upon m ~ e m e n t  
or a plurality of fixed wavelength lasers 61,62,63. A series of ofthe eye away from the focal Point Or SO that a Clinician is 
one or more bandpass filteridetector elements 65, 66, 67 alerted as to the m ~ e m e n t .  For example, upon transmission 
operatively associatedwith amplifiers and an analog to digital 30 ofthe laser pulse to the selectedregion in the eye, a sensor can 
converter 68 is used to sample the spectrum of the collected be concurrently operated and used to detect m ~ e m e n t  ofthe 
light. The center wavelength and bandwidth of each filter may retina away from the target focal Point. 
be chosen to correspond with a different Raman spectral peak The excitation laser light source can be any suitable laser 
of aqueous humor important for quantification of the selected beam source which can generate a suitable laser beam signal 
substance (such as alcohol, an illegal narcotic or banned 35 at a desired frequency output.Adistributedfeedback1aser can 
substance, a poison, or glucose). If this laser is tunable over be used to reduce instrument size. Tunable or multiple fixed 
about a nanometer or so, subtraction of the fluorescent com- frequency lasers can be combined with bandpass filters (Pup- 
ponents of the acquired spectrum may be possible as dis- pels et al., AppZiedSpectroscopy 47,1256-67 (1993)) that can 
cussed earlier. Using a laser with a wider tuning range can generate pulses for Raman scattering at wavelengths that 
allow the Raman shifted spectra to be scanned or slid across 40 provide optimum information for multivariate analysis (this 
a smallernumber of bandpass filteridetectors. Since semicon- can reduce the cost and size of the instrument compared to the 
ductor lasers with extremely wide tuning ranges are not com- use of holographic filters or gratings). 
merciallY readily available, One may instead use a set of The laser beam can be pulsed from the generator or from 
narrowly tunable lasers each with a different center wave- 45 the optical system to provide the desired length and power or 
length as the laser means in conjunction with a series of energy to the tissue in the eye, The power of the excitation 
bandpass filteridetectors for this purpose. Other suitable light laser beam pulse should be sufficiently low to avoid tissue 
sources can also be used. toxicity, but sufficiently high to provide a measurable Raman 
Advantageously, the systems described hereinmay be con- signal from the aqueous humor. In general, the laser beam 
figured so that optical components need not and do not con- 5o pulse will be at a wavelength of from 400 to 900 nanometers. 
tact the cornea ofthe eye during use, whichmany patients find In some embodiments, the laser wavelength can be a wave- 
objectionable (e.g., by providing a suitable monocular eye length of 780 to 860 nanometers to reduce fluorescence, 
cup for contacting the orbit around the eye). increase tissue penetration, and reduce phototoxicity to the 
The apparatus of the invention can be implemented as a eye. In other embodiments, the wavelength Can be generated 
spectrometer base unit attached by a fiberoptic cable to an 55 ata lower wavelength, such as between400-700nanometers, 
ocular probe, or as a single integrated unit including foreop- so as to increase the signal to noise ratio of the signal and/or 
tics, spectrometer, detector, computer and display. The appa- to deCrease the Power level ofthe signal in the eye. 
ratus can be configured as a relatively lightweight and por- The duration of the pulse can be from 1 to 60 seconds in 
table device. In some embodiments, the optics and laser length, and typically is from about 5-20 seconds long. 
sourcecanallbeconfiguredtobeheldinahousingwhichcan 60 The total energy of the laser pulse transmitted to the eye 
be mounted on the user as a headset, Or on a Portable Platform will typically be between 70-500 millijoules, with instanta- 
device similar to vision screening or vision correction devices neous power preferably not exceeding about 30-50 milli- 
used during vision exams. watts. The optical components of the apparatus used to carry 
As noted above, a visual fixation target such as a mirror, out the method are preferably configured so that energy on the 
LED, or display such as an active liquid crystal matrix display 65 retina of the eye (as well as other areas susceptible to tissue 
or the like can be built into the optical apparatus such that it is toxicity, such as the lens and cornea) transmitted from the 
held in the housing in visual communication with the patient excitation laser beam pulse is not greater than 3000 mWicm2, 
as desired. 
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more preferably not greater than 1000-2000 mW/cm2, and 
even more preferably, below about 500 mW/cm2. 
In certain embodiments, a low energy excitation wave can 
be used to generate the Raman signal spectrum. “Low 
energy”, as used herein, means power which is on the order of 
about 10-400 mJ or less, and typically between about 70-330 
mJ. The energy exposure will depend on the power and pulse 
length of the excitation pulse. Longer wavelength pulses (i.e., 
above 700 nm) may be used, typically with energy closer to 
the higher end of the scale, while lower wavelengths (400-700 
nm) may be able to employ lower energy exposure levels. In 
one embodiment, a wavelength of about 633 nm can be used 
for a pulse of about 5-10 seconds corresponding to about a 2 
mW power exposure level and between a 10-20 mJ energy 
exposure to the patient’s eye for each measurement or moni- 
toring signal obtained. In other embodiments, an optical exci- 
tation pulse may have a 785 nm wavelength (or other suitable 
wavelength), and a pulse length of about 20 ms and a power 
rating of about 15 mW. In another embodiment, a 5 sec, 16 
mW pulse (having a energy exposure level of about 75 mJ) 
can be used to obtain the in vivo reading of a substance such 
as a cancer treatment agent in the selected region of the eye 
(typically the AH). Thus, an energy exposure of under about 
100 mJ can be used in certain embodiments. In particular 
embodiments, an excitation light having a wavelength of 
about 406.7 nm can be employed. The 400 nm excitation 
wavelength level or range may be particular suitable where a 
resonant Raman signal may be generated by a selected sub- 
stance or molecule. 
For multiple measurements, the devices may be able to be 
configured to focus on a different eye, alternating the eye to 
which the light is transmitted, to reduce the amount of expo- 
sure to any one eye. 
FIG. 30 illustrates yet another embodiment of a device 
suitable for obtaining a Raman spectra ofthe eye of a subject. 
This device is compact, portable, and inexpensive, typically 
requiring only a diode laser, a filter, lens, and detector. The 
device can be directed to operate at a fixed excitation wave- 
length. As shown, the device includes a relatively inexpensive 
diode laser lOL, an optically-formed notch filter 21, a detec- 
tor 32, and a beam splitter 17. In certain embodiments, the 
diode laser 1OL has a fixed operational wavelength. Typically 
the device is configured to detect a predetermined substance 
and, as such, the excitation wavelength of the laser is pre- 
selected to correspond to a wavelength that substantially cor- 
responds to or approaches the resonant Raman (“RR’) wave- 
length for the predetermined substance of interest (but is 
above 400 nm). As used herein, the term “resonant Raman” 
means an excitation wavelength that amplifies the (detected) 
Raman signal at least about 100 times over non-resonant or 
weakly resonant excitation wavelengths or relative to the 
normal baseline chemicals present in the eye; this term is 
intended to include strongly pre- or post-resonant wave- 
lengths. 
The above design may be particularly suitable to detect 
substances with a molecule of interest that is resonant or 
pre-resonant in the 400-1000 nm range. Some molecules, 
notably ethanol, are not resonant over this range, but have a 
peak that is relatively strong at high physiological concentra- 
tions in which it is used (such as recreational intake). The 
same instrument design therefore can be used to test for 
ethanol since the blood concentration is very high (0.01- 
0.4%) (such as to test for drivers that may be impaired). Of 
course, this rationale applies to other analytes or substances 
that may be present in increased blood concentrations. Also, 
if a molecule is not going to be resonant or strongly pre- 
resonant, then the excitation wavelength can be chosen to 
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avoid or reduce fluorescence-usually by employing an exci- 
tation wavelength in the range of about 600-900 nm. 
Typically, the excitation wavelength is above 400 nm (be- 
tween about 400-600 nm) and corresponds to a portion of the 
absorption spectrum. Absorption is non-negative since it is 
defined as the -log (?! transmission). The excitation wave- 
length can be chosen to increase or maximize the signal to 
noise ratio. This can be done by making the signal bigger, by 
inducing resonant Raman by selecting an excitation close to 
the absorption band of the molecule (but above 400 nm) or by 
reducing the noise-i.e. reducing fluorescence by operating 
at a longer wavelength (e.g., 785 nm) for substances that 
cannot be made Raman resonant or strongly pre-resonant in 
the 400-1000 nm range. The signal enhancement for reso- 
nance is sufficiently increased that one should attempt to 
induce it when possible. However, it is noted that, in practice, 
many molecules may not be resonant or strongly pre-resonant 
in the 400-1000 nm wavelength range although certain drugs 
or other analytes of interest may be resonant or strongly 
pre-resonant in the 400-600 nm range. In particular embodi- 
ments, a wavelength of under about 450 nm, such as about 
405-410 nm, may be employed. 
The excitationrange is chosen to be above 400 nm because 
wavelengths below 400 nm may induce the formation of 
cataracts. Silicon CCD detectors are typically used in Raman 
spectrometers. The long wavelength cut-off for these detec- 
tors is slightly over 1000 nm. Therefore, to allow for Raman 
shifted light, the device can be configured to operate with an 
excitation wavelength range from about 400-900 nm depend- 
ing on the application. 
The device can be configured to provide an exposure time 
(expose the eye to the light) of about 10-15 seconds or less 
with an associated power of about 1-5 mW, and typically 
about 1-2 mW. 
As shown in FIG. 30, the device can be configured with a 
sine wave generator 10s  operably associated with the diode 
laser 1OL and the detector 32 to modulate the signal and 
improve SNR. A mixer 10M can be used to integrate the sine 
wave generator 10s and the detector 32 with the low pass 
filter 10F as is well known to those of skill in the art. 
In certain embodiments, the device can be configured so 
that, in operation, the sine wave generator 10s modulates the 
laser light. Generally stated, the detected light is Raman scat- 
tered off the sample and is modulated in a similar fashion. The 
detector measures this intensity and converts it into an elec- 
trical current. The detector also picks up noise from the ambi- 
ent light and other sources. The mixer 10M multiplies this 
detected signal by a reference sine wave, producing a signal. 
The low pass filter rejects the high frequency terms and passes 
the low frequency term of the Raman scattered light. Thus 
above-described operation may be described as coherent sig- 
nal detection and is a detection technique commonly 
exploited by lock-in amplifiers. As is known to those of skill 
in the art, other designs may also be used such as without 
modulation of the laser beam and/or post-processing module. 
In certain embodiments, the device can be configured with 
improved signal to noise ratio of the overall instrument by 
post-processing the detector 32 signal by using coherent 
detection, similar to methods employed by a lock-in amplifier 
as is well known to those of skill in the art. 
FIGS. 26 and 29 illustrate a RR spectrum generated at 
406.7 nm excitation wavelength for two different substances 
of interest, the peaks having increased intensity over spec- 
trums generated at non-resonant or weakly resonant wave- 
lengths. FIG. 26 illustrates the RR spectrum of a chemothera- 
peutic agent and FIG. 29 illustrates the RR spectrum of an 
anti-fungal agent. However, even for non-resonance wave- 
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lengths that approach the peak absorption wavelength of the over the eye socket(s) to seal the eye(s) from ambient lighting, 
compound, the Raman signal intensity may increase suffi- (b) the excitation pulse light is efficiently directed into the eye 
ciently to serve as an acceptable operable excitation wave- (without scattering into the environment), (c) and the light 
length. The particular excitation wavelength will depend on reflected from the eye (such as the AH) can be captured, but 
the drug or analyte of interest and can be selected so that, in 5 no physical contact with the cornea of the eye itself is 
operation, it can amplify the detected intensity of the Raman required. For example, a monocular eye cup (or binocular eye 
spectrum signal substantially, such as by about 100 times to cups) can be used to contact the orbit around the eye and yet 
1,000 or greater (even up to about 100,000 times in certain space the optical components from contacting the cornea. The 
circumstances) over that of signals generated with excitation scattered light from the illumination light pulse is then 
signals that depart greater than 200 nm, away from the peak i o  detected (Block 120). 
wavelength in the absorption spectrum. As such, in certain 
embodiments, the excitation wavelength may be chosen so 
that it is about 100 nm or less above the peak absorption 
wavelength in the absorption spectrum. 
interest in the RR spectrum (at a predetermined wavelength 
shift of interest), such as the peak at 1576icm or 117licm in 
FIG. 26 or the peak at 1152icm or 1554icm in FIG. 29. Of 
course, as noted above in other embodiments, the device can 
be confirmred to detect multinle neaks or at multinle wave- 20 
The device can be configured to detect a single peak of 15 
During the transmission and detection steps, the eye can be 
focused to a desired location or target spot (Block 105) to help 
direct the excitation light out of and into the eye in a repeat- 
able and reliable manner (to define a consistent transmission 
path so that the reflected light is attributed to proper and 
reliable illumination oftheVH, AH, or conjunctiva vessel(s)). 
In so doing, a manual or autofocusing technique can be used. 
For manual focusing, various methods can be used to allow 
the user to adjust the focus. For example, a pinwheel can be 
turned clockwise or counterclockwise to focus on anobiect or u I I  
lengths (adding notch filters or a tunable laser, and the like, as text or other visual fixation target to be displayed in the device 
is well known to those of skill in the art). (typically the object or text is displayed in a miniaturized 
In certain embodiments, the chemical or analyte concen- display (such as an active matrix display) positioned about the 
tration in the blood can be measured within a 90-99% accu- opening through which the light is transmitted proximate the 
racy level as determined by extracting the aqueous humor, 25 light transmission path). For example, LED's or active matrix 
putting it in a test tube and measuring the Raman spectrum. displays can be used to generate text or a blinking or continu- 
The band of interest is typically in the 200-3200 cm-' band. ous light, which attracts the visual attention of the subject and 
Any suitable detector 32 can be used to detect a Raman which the subject watches or reads during the transmission 
spectrum from illuminated aqueous humor. In certain and detecting steps. 
embodiments. a CCD detector or CCD camera can be used to 30 Similarlv. for autofocusinp. the subiect can look to the 
detect reflective light as they may exhibit increased sensitivity 
over other types of detectors. The CCD detector preferably is 
configured to have high quantum efficiency in the near infra- 
red range. The high quantum efficiency may be achieved by 
any suitable means, such as employing a back thinned detec- 
tor, but one sufficiently thick to reduce etalon effect. 
The devices of the invention can be operatively associated 
with a patient's medical equipment such as an insulin pump 
(for D-glucose) or to a dialysis machine (forurea) by wireless 
or wired electrical or fiber ontic lines. radio freauencv trans- 
_.I '2, 
visual fixation target mounted in the device in visual commu- 
nication with the eye. The presentation of the object can be 
automatically stepped through a visual protocol which can 
magnify or adjust the visual presentation until the subject can 
35 read or recognize the object. When this happens, the reading 
or recognition indicates that the focus is sufficient, and the 
reading can be taken (i.e., the transmission and detection of 
light). Autofocusing systems with corrected optic systems are 
well known to those of skill in the art. For example, optic 
40 svstems similar to those used to assess vision and determine 
I ,  
mitters and receivers or the like to provide information on the a suitable lens correction for a subject during vision exami- 
appropriate analyte that can then be used to control that equip- nations can be incorporated into the devices according to 
ment. For example, the reading can be used to automatically embodiments of the present invention. Although a contact 
activate or increase or decrease the output of the equipment lens may remain in place during the reading, it is preferred 
such as the insulin pump in response to blood glucose levels, 45 that glasses or other objects which may physically interfere 
or to regulate the dialysis machine. 
In telemedicine applications, the instrument of the inven- 
tion can be conveniently operatively associated with a remote 
read-out terminal through a communication link such as a 
telephone, cable, computer, modem, intranet, internet con- 
nection or other communication line with any suitable relay 
or interconnection means (such as an electrical or fiber optic 
lines, radio frequency transmitters and receivers, etc.) to pro- 
vide information on the blood or intracranial (blood-brain 
fluid) analyte to a remote physician or medical provider (e.g., 
through a telephone, cable, or wireless connection to a direct 
with the mounting of the device over the eyes, be removed 
during the test. 
The power or beam strength of the light pulse can be 
monitored so that fluctuation in the power or strength of the 
50 light beam which is transmitted to the user can be adjusted so 
that it the current andor heat is regulated to be substantially 
constant (constant current or heat) or numerically corrected 
for, typically in the signal processor 35s (Block 110). A 
Raman spectrum of the targeted region of the eye can then be 
55 generated based on the detected and corrected light spectro- 
scopic signal (Block 130). Typically, well-known statistical 
security (for in-home parole) or medical monitoring agency 
or to a selected destination on the intranet, internet, or world 
wide web). 
FIG. 11 illustrates method steps for obtaining spectro- 60 
graphic readings of the selected region of the eye of a subject 
according to certain embodiments ofthe present invention. As 
shown, an excitation or illumination light pulse is transmitted 
to the selected region of the eye of the subject (Block 100). In 
certain embodiments, this can be carried out by positioning a 65 
mask-like device over the eyes of the subject (similar to that 
used in eye exams) so that (a) the housing of the device aligns 
correlation or normalization techniques are used to generate 
the Raman spectrum from the scattered light data received at 
the detector. See e.g., Standard Practices fo r  Infrared, Mul- 
tivariate, Quantitative Analysis, ASTM E 1655-97; Beebe et 
al., An Introduction to Multivariate Calibration anddnalysis, 
Anal. Chem. 59, 1007A-10017A (1987); Draper et al., 
Applied Regression Analysis (2d ed., John Wiley and Sons, 
1981); Maliowski et al., FactorAnalysis in Chemistry (2ded., 
John Wiley and Sons, 1991); Mark, H., Principles and Prac- 
tice of Spectroscopic Calibration (John Wiley and Sons, 
1991); Martens et al., Multivariate Calibration (John Wiley 
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and Sons, 1989); and McClure, G., Ed., Computerized Quan- Spec., 36; 535-539 (1982); Kargacin et al. Zon Intensity and 
titative Znfrared Analysis, ASTM STP 934, ASTM (Philadel- Image Resolution in Seconda y Zon Mass Spectromety, Anal. 
phia, 1987). The contents of these references are hereby Chem., 58; 2300-2306 (1986); Lindberg et al., Partial Least 
incorporated by reference as if recited in full herein. Squares Method for  Spectrojuorimetric Analysis of Mixtures 
Thus, any number of suitable computational analysis may 5 of Humic Acid and Ligninsulfonate, Anal. Chem., 55; 643- 
be used including linear (e.g., algebraic or least squares/ 648 (1983); Lukco et al., The Use of GC-AESMultielement 
partial least squares) or nonlinear (e.g., artificial neural net- Simulated Distillation fo r  Petroleum Product Fingerprinting, 
works) multivariate analysis techniques, such as, multiple J. Chrom. Sci., 1993 March; Malinowski et al. FactorAnaly- 
linearregression (MLR), classical least-squares (CLS, K-ma- sis in Chemistry, 2nd edition, John Wiley and Sons, New 
trix), inverse-least-squares (ILS, P-matrix), principal compo- 10 York, 1991; Malinowski, E. R., Theory of the Distribution of 
nent regression (PCR, PCA, factor analysis), and partial least- Error Eigenvalues Resulting from Principal Component 
squares in latent variables (PbS). See Schulze et al., ArtiJicial Analysis with Applications to Spectroscopic Data, J. Chemo., 
neural network and classical least squares methods fo r  neu- 1; 33-40 (1987); Malinowski, E. R., Statistical F-Tests f o r  
rotransmitter mixture analysis, Jnl. Neuroscience Methods Abstract Factor Analysis and Target Testing, J. Chemo., 1 ; 
56(2); 155-167 (February 1995); and Wang et al., Analysis of 15 49-60 (1987); Malinowski, E. R. Theoy  of Error in Factor 
metabolites in aqueous solutions by using laser Raman spec- Analysis, Anal. Chem., 49; 606-612 (1 977); Malinowski, E. 
troscopy, Applied Optics, 32(6); 925-9 (February 1993). See R., Determination of the Number of Factors and the Experi- 
also Brown, C. W., Classical and Inverse Least-Squares mental Error in a Data Matrix, Anal. Chem., 49; 612-617 
Methods in Quantitative Spectral Analysis, Spectrosc., 1; (1977); Naes et al., Selection of Samples f o r  Calibration in 
23-37 (1 986); Brown, et al., “Matrix Representations and 20 Near-Znfrared Spectroscopy. Part I: General Principles Zllus- 
Criteria for Selecting Analytical Wavelengths for Multicom- trated by Example, Appl. Spec. 43; 328-335 (1989); Rao et 
ponent Spectroscopic Analysis”, Anal. Chem. 54; 1472-1479 al., Factor Analysis and Least-Squares Cuwe-Fitting of 
(1982); Carey et al., MulticomponentAnalysis using an Array Znfrared Spectra: An Application to the Study ofphase Tran- 
ofPiezoelectric CrystalSensors,Anal. Chem., 59; 1529-1534 sitions in Organic Molecules, Appl. Spec., 38; 795-803 
(1987); Haaland, D. M. Classical versus Inverse Least- 25 (1984); Schostack et al., Preferred Set Selection by Iterative 
Squares Methods in Quantitative Spectral Analyses, Spec- KqSetFactorAnalysis, Chemo. andIntel. Lab. Sys., 6; 21-29 
trosc. 2; 56-57 (1987); Haaland et al. Application of New (1989); Vaughan et al., Determination of Ni by ZCP-MS: 
Least-squares Methods fo r  the Quantitative ZnfraredAnalysis Correction of Oxide andHydroxideZnterferences Using Prin- 
of Multicomponent Samples, Appl. Spec., 36; 665-673 cipal Components Analysis, Appl. Spec., 44; 1685-1689 
(1982); Haaland et al., Improved Sensitivity ofznfrared Spec- 30 (1 990); Carey et al., MulticomponentAnalysis using an Array 
troscopy by the Application of Least Squares Methods, Appl. ofPiezoelectric CystalSensors, Anal. Chem., 59; 1529-1 534 
Spec. 34; 539-548 (1980); Haaland et al. Multivariate Least- (1987); Donahue et al., Analysis of Deoxyribonucleotides 
Squares Methods Applied to the Quantitative Spectral Analy- with Principal Component andpartial Least-Squares Regres- 
sis of Multicomponent Samples, Appl. Spec., 39; 73-84 sion of UVSpectra after Fourier Processing, Appl. Spec., 44; 
(1985); Kargacin et al. Zon Intensity andlmage Resolution in 35 407-413 (1990); Geladi et al., Partial Least-Squares Regres- 
Seconday Zon Mass Spectrometry, Anal. Chem. 58; 2300- sion: A Tutorial, Anal. Chim. Acra, 185; 1-17 (1986); Haa- 
2306 (1 986); Kisner et al. Multiple Analytical Frequencies land et al., Partial Least-SquaresMethods fo r  SpectralAnaly- 
and Standards fo r  the Least-Squares Spectrometric Analysis sis 1. Relation to Other Quantitative Calibration Methods 
ofserum Lipids, Anal. Chem., 55; 1703-1707 (1983); Kisner and the Extraction of Qualitative Information, Anal. Chem., 
et al., Simultaneous Determination of Triglycerides, Phos- 40 60; 1193-1202 (1988); Haaland et al., Partial Least-Squares 
pholipids, and Cholesteyl Esters by Znfrared Spectromety, Methods fo r  Spectral Analysis 2. Application to Simulated 
Anal. Chem., 54; 1479-1485 (1982); Lam, R. B. On the and Glass Spectral Data, Anal. Chem., 60; 1202-1208 
Relationship of Least Squares to Cross-correlation Quanti- (1988); Hanna et al., A Comparison ofMethods Usedfor the 
tative Spectral Analysis, Appl. Spec., 37; 567-569 (1983); Reconstruction of GC/FT-l7R Chromatograms, J. Chrom. 
Maris et al., Nonlinear Multicomponent Analysis by Znfrared 45 Sci., 17; 423-427 (1979); Kelly et al., Prediction of Gasoline 
Spectrophotornetry, Anal. Chem., 55; 1694-1703 (1983); Octane Numbers from Near-infrared Spectral Features in the 
McClure, G. L. et al. Application of Computerized Quantita- range 660-121 5 nm,Anal. Chem., 61; 313-320 (1989); Lind- 
tive Znfrared Spectroscopy to the Determination of the Prin- berg et al., Partial Least-Squares Method for  Spectrojuori- 
cipal Lipids Found in Blood Serum, Computerized Quantita- metric Analysis of Mixtures of Humic Acid and Ligninsul- 
tive InfraredAnalysis, ASTM STP 934, G. L; McClure, Ed. 50 fonate, Anal. Chem., 55; 643-648 (1983); and Otto et al., 
American Society for Testing and Materials, Philadelphia, Spectrophotometric Multicomponent Analysis Applied to 
13; 1-154 (1987); Otto, M. et al. Spectrophotometric Multi- TraceMetalDeterminations,Anal. Chem., 57; 63-69 (1985). 
component Analysis Applied to Trace Metal Determinations, The contents of these references are hereby incorporated by 
Anal. Chem., 57; 63-69 (1985);Antoonet al. FactorAnalysis reference as if recited in full herein. 
Applied to Fourier Transform Znfrared Spectra, Appl. Spec., 55 FIG. 1OC illustrates that the device 5 may include a closed 
33; 351-357 (1979); Are et al., On the Efect of Calibration loop feedback system 5f for monitoring and regulating the 
and the Accuracy of NZR Spectroscopy with High Levels of strength or intensity of the light excitation beam output to the 
Noisein theReference Value,Appl. Spec. 45; 109-1 15 (1991); eye of the subject. The feedback system 5f may employ a 
Bulmer et al. Factor Analysis as a Complement to Band beam splitter positioned to bleed off a portion of the beam at 
Resolution Techniques. I. The Method and its Application to 60 a location which is proximate to the aperture (the beam outlet 
Self-Association ofAcetic Acid, J. Phys. Chem. 77; 256-262 port) and substantially continuously detect the beam power, 
(1973); Culler et al. Factor Analysis Applied to a Silane intensity, or energy associated therewith to monitor the power 
Coupling Agent on E-Glass Fiber System”, Appl. Spec., 38; of the excitation beam as it is transmitted out of the device. 
495-500 (1984); Dale et al., Principal ComponentAnalysis of Other embodiments can include dynamically monitoring the 
difuse Near-Znfrared Rejectance Data From Paper Cur- 6 5  current or power load of the laser 10 to adjust for temperature 
rency, Appl. Spec., 43; 1399-1405 (1989); Gillette et al., or other operational drift or power fluctuation during opera- 
Noise Reduction via Factor Analysis in FT-Zr Spectra, Appl. tion. The signal processor 35s can then adjust the input to the 
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laser as needed and/or store the excitation beam data so that 
the Raman spectrum can be adjusted to reflect the actual beam 
energy or power transmitted to the user. 
FIG. 10D illustrates one operational embodiment of a 
device with power regulation according to the present inven- 
tion. As shown, the laser 10 is operably associated with a 
power supply lop. The laser 10 directs the light through a 
fiber optic cable 40 which includes or is coupled to a fiber 
optic splitter 40s which directs or bleeds a small portion of the 
light away from the primary light transmission path (and into 
the eye of the patient). A substantial portion of the light 
remains in the primary light transmission path and is directed 
into the Raman probe head 15 probe which can, in operation, 
be positioned adjacent the eye 12 of the patient. The Raman 
spectrometer 32 can be positioned in communication with the 
Raman probe so as to be able to detect the light upon its return 
(in the return path). 
As shown, the splitter 40s may split about 1% of the exci- 
tation light away from the primary beam to a detection path 
115 and into a photodetector 116 (or other suitable sensor). 
The photodetector 116 is in electrical communication with an 
A/D (analog to digital) converter 118, which converts the 
corresponding electrical signal so that it can be digitally input 
into the processor 35. Thus, the voltage or current from the 
photodetector 116 is measured and digitized (preferably in a 
substantially continuous or continuous manner during opera- 
tion of the device) and the information transmitted to the 
processor 35 (typically a computer). The computer or proces- 
sor 35 can then measure the laser power and computationally 
determine a new adjusted current (or voltage) to adjust the 
laser 10 output to the desired or target output value such that 
it is able to be held to within about 95% of the target output 
strength. In certain embodiments, the output signal strength 
can be held substantially constant such as within at least about 
98-99%. The computer output can be converted back into 
analog form via a DIA converter 119 which is used to regulate 
the voltage power supply lop which, in turn, regulates the 
input to the laser 10. 
The optical system 15xi may also be configured to transmit 
the excitation beam such that it presents a wider cone to focus 
to the retina in a manner which is able to cover a larger area of 
the selected region in the eye to thereby operate with a lower 
energyiarea ratio (such as, for at least some AH applications, 
configuring the optical system such that the numerical aper- 
tures of the input optic system 15xi is substantially matched to 
the output optic system 15x0 (or spectrometer). In certain 
embodiments, a numerical aperture of about 0.2-0.5 can be 
used. The graph in FIG. 20C shows a sample power density 
and exposed retinal area for a numerical aperture of 0.25 and 
a lox objective (Point A) and a larger numerical aperture of 
about a 0.4 (23.6 degrees for a 20x objective) at Point B. 
FIGS. 20A-20C illustrate optical power density calcula- 
tions performed using a canonical model of the adult eye of a 
human (FIG. 20A). Typically, optical toxicity power limita- 
tions for the eye are established by regulatory agencies. 
FIG. 20A shows a diagram ofthe adult eye exposed to light 
through an eyepiece with a corresponding objective and 
numerical aperture. Marginal rays from this eyepiece are 
shown focusing through the cornea and into the aqueous 
humor within the anterior chamber. The confocal optical con- 
figuration of the instrument allows it to sample Raman scat- 
tered light in the region near the focal spot (and substantially 
isolated to that region). Thus, in certain embodiments, the 
optic design can be such that scattering from the cornea or the 
intraocular lens can be reduced and can be confocally blocked 
from the instrument’s fiber-optic entrance aperture within the 
optical probehead (FIG. 10d, 15 probe). 
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FIG. 20A also shows the nodepoint (N) originally derived 
by Gullstrand. Gullstrand used special instrumentation to 
observe Purkinje reflections from both sides ofthe cornea and 
lens to develop a simple eye model which lumped the power 
5 of the cornea and the intraocular lens into a single equivalent 
lens with node point (N). Based on the knowledge of the 
position of node point (N) relative to the retina, one can 
calculate sizes of objects on the retinal surface. This informa- 
tion can be used to compute the surface area of the retina 
i o  exposed by the numerical aperture (NA) (such as NA=0.25 or 
NA=0.4 according to certain embodiments of the design of 
the device and the associated eyepiece). 
In this model, rays passing through (N) can be treated as if 
they are unrefracted as they travel through the eye and onto 
15 the retina. One can construct rays that pass through (N) but are 
also collinear with the eyepieces marginal rays as shown. A 
pair of collinear rays entering the lens equivalent model 
should focus on the retina. Going through this exercise with 
both pairs ofmarginal rays ofthe eyepiece shows that one can 
20 treat the incident beam as a point source which emanates from 
(N) at an angle Bi, the same angle as the marginal rays make 
with the optical axis. 
As shown in FIG. 20B, simple calculus can be employed to 
derive an expression for the surface area of a sphere over a 
25 solid angle delineated by Bc, the angle of a ray from normal 
that extends to the margins of the surface area exposed on the 
sphere. The expression for surface area is given by equation 1. 
A=2nR2(1-cos e,) Equation 1 
30 Bi is given (calculated as sin-’ of NA of the eyepiece) and 
not Bc, an expression can be derived which relates these as a 
function of the radius of the globe and the relative position of 
N given by x,. As shown by equation 2 in FIG. 20B, trigo- 
nometry can be used to derive this relationship. For any Bi, 
35 equation 2 can be solved numerically for Bc, using the New- 
ton-Rapson method. 
R sin e,=@ cos B,+x,) tan 8, Equation 2 
FIG. 20C is a graph which plots exposed retinal surface 
40 area (right vertical axis) and power density assuming a 30 
mW illumination (on the left vertical axis) on the retina as a 
function of various eyepiece designs defined by the angle of 
incidence “Bi”. The line indicated at the angle of incidence 
just below 15 degrees (Point A) corresponds to the numerical 
45 aperture 0.25 used for obtaining certain of the experimental 
data shown or described herein. The angle of incidence asso- 
ciated with a numerical aperture of 0.4 is at about 23.6 
degrees (larger exposedretina area and lower power density), 
shown at Point B, used to obtain the data illustrated in FIGS. 
50 21A-C. This angle can also be expressed in terms of NA or 
“f ’-number (the focal length divided of the fully illuminated 
diameter of the limiting aperture). The numerical aperture of 
the entire system places an upper bound on the effective 
numerical aperture. For example, the numerical aperture of 
55 the embodiment of the device 5 of the spectrometer used to 
determine certain of the described results is fil.8 
(NA=0.267). However, the fiber optic cable between the spec- 
trometer and the probe head, limits the numerical aperture to 
fi2.0 (NA=0.24). Thus using an objective at a higher f number 
60 than the fiber is counterproductive since Raman scattered 
light at the outer angles is not captured by the fiber. Using the 
instrument with the same incident power but with an objective 
with an f number smaller than fi2 will generally result in 
higher power densities on the retina with no increase in 
65 Raman signal gain. This is because maximum collection effi- 
ciency is achieved at a particular by matching the f number of 
the eyepiece to that of the system. The present invention can 
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provide designs which can be considered close to optimal, by processor. Water is typically not an issue for Raman spectros- 
configuring the system with an f number which is approxi- copy, but a water spectrum can be subtracted if desired. 
mately equal to the eyepiece numerical aperture. Using 30 For the difference spectrum adjustment embodiments, the 
mW of illumination, one embodiment can provide a lens blood level of the selected substance (or the cerebral spinal 
configuration which exposes about 0.58 cm2 of the retina to a 5 fluid level) for the subject can be determined from the differ- 
power density of about 5 1.5 mW/cm2. ence spectrum by correlating the difference spectrum to pre- 
FIG. 18 illustrates that the illumination target in the eye can determined spectrums or data representing the concentration 
be the vitreous humor, a substantially clear gel-like region of a particular substance. 
positioned beyond the aqueous humor. The devices described The computational analysis can use the differential spec- 
herein can be configured to operate similarly to that for the i o  trum or the non-differential spectrum depending on the 
AH target, Le., by transmitting the excitation beam to a deeper 
depth into the eye and into theVH (through the lens andor the 
portion of the eye accessible when the eye is open), illumi- 
nating same and then detecting the transmitted light returned 
therefrom. The energy levels are preferably as noted above for 15 
the AH. As the Raman signal from VH may exhibit increased 
fluorescence, signal correction (subtraction, differentiation, 
etc.) may be used to obtaiddetect the desired signal data. 
FIG. 19 illustrates that the illumination target in the eye can 
be one or more blood vessels located on the coniunctiva at the 20 
desired application (typically associated with the degree of 
fluorescence of the selected region of the eye to determine the 
Raman spectrum and identify the presence of any selected 
spectroscopic profile or “signatures” having peaks in a spatial 
region of the spectrum, which, in turn, allows for the identi- 
fication of the presence or concentration of a selected sub- 
stance in the selectedregion of the eye. The correlation can be 
based on an empirically based model, formula, or matrix of 
test data garnered from an actual subject or from in vitro 
samnles. The data can be correlated and the end results com- 
outer surface of the eye. Using the conjunctiva vessel(s) can puted in a hardware andor software processor. The model can 
allow a direct blood level measurement to be obtained as this be obtained through linear (e.g., partial least squares) or non- 
embodiment can focus to the blood flowing in the vessel (i.e., linear (e.g., artificial neural networks) multivariate analysis. 
the blood itself to directly determine the targeted blood level In some embodiments, it may be important that a reference 
measurement). In operation, the excitation beam is focused to 25 set or reference standards of known substances and concen- 
at least one blood vessel on the externally accessible surface trations be predetermined and stored for computational ref- 
of the eye to illuminate the blood flowing in the blood vessel erence. For example, a training set of Raman spectra can be 
(because the bloodvessel is located on the outer surface of the used. The training set can include samples from (or represen- 
eye, there is no need to illuminate through skin). The targeted tative of) the selected region of the eye such as the aqueous 
blood vessel can be anv of the blood vessels located on or 30 humor with a broad range of concentrations of the Raman 
adjacent the conjunctiva of the eye (typically these are visu- 
ally apparent), such as the long ciliary arteries or veins. One 
suitable target location may be one of the blood vessels 
located outside the iris away form the pupil. The detected 
Raman spectrum signal can be analyzed and a direct blood 35 
level measurement of the analyte of interest obtained. In 
certain embodiments, at least two readings can be taken to 
obtain data samples at different points of time to watch the 
spectra change. For example, one can attempt to include data 
associated with the vessel at a noint in time when the blood 40 
u 
scattering metabolites. In the training set, the principal 
Raman-scattering metabolites (or “Raman active com- 
pounds”) should be provided such that they (for at least the 
AH this may include glucose, lactate, urea, ascorbate, and any 
exogeneous compounds or drugs present) preferably do not 
vary co-linearly with one another among the samples in the 
training set. For direct bloodmeasurements (Le., the conjunc- 
tiva vessel measurements), the Raman active compounds will 
be those typically present in the blood. The model can be 
nroduced with snectra samnles obtained from one or more 
cells are absent in the illuminated region in the vessel. Fur- prior subjects, with spectra samples obtainedfrom the subject 
ther, the Raman signal can be processed (discardedor filtered) from whom the current blood level of the analyte of interest is 
to remove the data corresponding to red blood cells to being determined (in which case that subject would be 
enhance the desired signal of the analyte of interest (such as required to provide a blood sample for determination of the 
glucose). In some embodiments, the beam can be altered to 45 blood concentration of the analyte of interest), or from test 
disregard the Raman signal of the blood portion and to pursue vials or artificial AH’S with known concentrations of selected 
the Raman signal ofplasma (such as by shuttering the beam to metabolites andor the substance of interest. Thus, for an 
discard the blood portion or to delay upon detection of signal AH-basedmeasurement, a training set can be used, with vials 
associated with blood). having a plurality of constituents, those normally present in 
In certain embodiments, the fluorescence spectrum for the 50 the eye (including lactate, urea, and ascorbate) and in the 
aqueous humor can be subtracted from the Raman spectrum 
by stimulating the aqueous humor with a second excitation 
laser light pulse at a wavelength slightly different from that of 
the first pulse (e.g., up to two nanometers from the first pulse), 
and then subtracting one spectrum from the other in a proces- 55 
sor in accordance with conventional techniques. Such tech- 
niques are known. See, e.g., Funfschilling and Williams, 
Applied Spectroscopy 30, 443 (1976); Baraga et al., Applied 
Spectroscopy 46, 187 (1992); Wicksted et al., Applied Spec- 
troscopy 49,987 (1995)). In the alternative, the fluorescence 60 
spectrum can be subtracted out through the use of software or 
substance of interest. 
In some embodiments, to provide an atypical training 
sample, an artificial cover (such as a contact lens) may be 
intentionally positioned over the aqueous humor being used 
to generate a sample in a training set. This cover or lens can 
operate to cause the actual AH to have abnormal levels of 
lactic acid (a lactic acid buildup) as it is inhibited fromnormal 
operation. 
Typically, the training set uses at least 10, and more pref- 
erably 20, 25, 30 or more Raman spectra samples (and 
samples of the corresponding blood levels of each of the 
other processing techniques. Thus, the term “subtraction” as selected analytes of interest) with substantial intersample 
used herein is intended to include techniques such as filtering variability in the levels of the major Raman scattering 
as well as taking the derivatives of the signal. While not metabolites (e.g., glucose, ascorbate, lactate, urea, and any 
essential, other potentially interfering spectra or signals such 65 drugs, analytes, or exogenous compounds present). The con- 
as Raman scattering from the lens, iris, or cornea can also be centration of the analyte of interest (in either the blood or 
filtered or subtracted through a hardware andor software aqueous humor) preferably varies by at least a factor of 2,5, 
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10 or 20 or more from the sample with the lowest concentra- 
tion to the sample with the highest concentration. This may 
include providing concentrations of constituents less than and 
greatly above their normal levels such as 0.5 times to 15 times 
the normal levels (for the AH this can include urea, ascorbate, 
lactate, and, can also include glucose or other substances of 
interest, in saline). The mixtures can be prepared such that 
they provide a statistically uniform distribution with no bias/ 
co-linearity (i.e., 100 different mixtures of four random sub- 
stances in the test tube). It is anticipated that the calibration 
curve can be biased to cluster a training set biased within the 
normal or low range (i.e., to be skewed, depending on the 
application). 
The concentration ratios or correlations may require devel- 
opment of the model using subjects with multiple different 
diseases (e.g., renal failure, diabetes, seizures, mitochondrial 
myopathies, sickle cell disease, heart failure, bloodclots, etc.) 
and/or other parameters such as gender, age, weight, national 
origin, etc. For human applications, the model may even be 
determined with spectra samples obtained from animals, par- 
ticularly primates. The sample of the selected region in the 
eye may be a natural sample (human or animal), or may be a 
man-made or surrogate aqueous humor sample created to 
mimic natural samples, where the blood level is calculated 
from a priori knowledge of the relationship between blood 
levels and aqueous humor levels for the analyte(s) of interest 
(for the blood level measurements). Similarly, for the cerebral 
spinal or intracranial fluid, the aqueous humor sample may be 
a natural sample (human or animal), or may be a man-made or 
surrogate aqueous humor sample created to mimic natural 
samples, where the level is calculated from a priori knowl- 
edge of the relationship between cerebral spinal or intracra- 
nial levels and aqueous humor levels for the analyte(s) of 
interest. 
For example, when the analyte of interest is glucose, the 
training set of samples for the empirical model can comprise 
at least 20, 25 or 30 aqueous humor spectra samples. The 
samples can include varying levels of constituents which 
correspond to measured blood glucose levels, where the prin- 
cipal Raman active compounds in the aqueous humor 
samples (glucose, ascorbate, lactate, urea, and preferably any 
exogenous compounds such as drugs) vary substantially non- 
colinearly among the samples. The physiological levels of the 
blood and/or corresponding aqueous humor glucose concen- 
trationinthetest samplescanrangefromOor50mgidLto 800 
or 1,000 mgidL, typically including at least a 100,200,300 or 
400 mgidL difference in concentration between the sample 
with the lowest concentration and the sample with the highest 
concentration. 
Turning now to FIG. 12, one embodiment of the invention 
illustrated therein is particularly suited for the non-invasive 
detection, identification and/or measurement of poison in the 
blood. A plurality of reference standard spectroscopic spec- 
trum signals are generated (Block 150). The reference signals 
can be converted into data defining peaks and frequencies and 
features of interest and the standards can correspond to in 
vitro samples of a plurality of different selected substances, 
and in some embodiments, each presented at different con- 
centration levels (Block 155). The data associated with the 
reference standards can be programmed into a computer or 
signal processor and made available for subsequent use. As 
noted above, the reference standards can correspond to a 
plurality of different Raman spectrum data corresponding to 
a plurality of different drugs, or typical or common poisonous 
substances. For example, Raman signatures of the most 
prevalent chemicals associated with pediatric poison control 
calls or emergency room visits can be analyzed in various 
concentrations to define an associated Raman signature. 
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These can include common over-the-counter household 
drugs or medicinal supplies such as the drugs identified by 
brand names acetaminophen, ibuprofen, isopropyl alcohol, 
methanol, ethylene glycol and the like, or prescription drugs 
5 such as blood pressure medicines (such as HYTRIN), ste- 
roids, antibiotics, birth control pills, and the like, as well as 
household cleaning chemicals, pesticides, herbicides, and 
petroleum products. 
An in situ Raman spectroscopic reading can be obtained of 
lo the subject (Block 160). The subject may have been exposed 
to an unknown poison or substance. In some embodiments, 
the term “unknown poison or substance” can also include an 
unknown quantity of a known substance. For example, a 
guardian acknowledges that a TYLENOL bottle was found 
l5 empty next to a young child, but it is unknown how many pills 
may have been in the bottle. The present invention may be 
able to determine whether a toxic amount was consumed. 
In any event, the presence (or absence) of at least one 
2o selected substance in the subject can be identified (Block 
170). The amount of the identified substance in the selected 
region of the eye ofthe subject may also be determined. Based 
on the amount in the eye, an amount (a) in the blood and/or (b) 
in the cerebral spinal fluid or intracranial fluid can be estab- 
25 lished (anticipating that the amount in the AH can be corre- 
lated to either the amount in the blood or the amount in the 
cerebral spinal or intracranial fluid), thus allowing the pres- 
ence and concentration to be indirectly established or esti- 
mated based on the detected presence and/or concentration in 
3o the selected region of the eye (such as the AH) (Block 180). 
Physiological differences among different population seg- 
ments may require determination of different correlation fac- 
tors for each population segment (segmented by selected 
parameters of interest such as by age, gender, national origin, 
In one embodiment, a Raman spectraispectrum poison 
control substance identification database can be generated 
and the in situ reading then compared thereto so that a screen- 
ing and assessment of the identity ofwhich poison or poisons 
40 that the subject has been exposed can be readily identified by 
matching the in situ reading to one or more of the pre-deter- 
mined and digitally stored Raman spectra. The database of 
selected substances may be held on a central database which 
can be remotely located or located at regional or selected 
45 locations (via the internet, intranet, or other communication 
means) and the localizedreading can be uplinked to the larger 
database for a more comprehensive screening. Alternatively, 
the signal processor or computer associated with the Raman 
excitatioddetection device or system may be configured with 
50 data corresponding to the most common types of substances 
and if a localized scan fails to match the in situ reading, amore 
comprehensive computational screening can be performed 
off-line or at the remote or larger database location. 
As shown in FIG. 13, another embodiment of the present 
55 invention is directed to an in vivo method for monitoring the 
administration of a targeted therapy such as a drug, chemical, 
gene, or other therapy, given to a subject for treatment of a 
condition in the brain (such as various cancers or neurologic 
conditions). For example, the present invention may be used 
60 during a treatment sessionusing delivery of a cytotoxic agent 
to treat a cancerous tumor in the brain (or to other patients for 
specialized drug treatments targeted to the brain such as for 
treating neurological impairments in the brain). The method 
includes administering a dose of a selected treatment agent 
65 (typically chemotherapy) to a subject (Block 200). The 
dynamics of the blood brain barrier are deliberately or inten- 
tionally altered from the normal state (Block 210). The 
35 etc.1 
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dynamics or functiodoperation of the blood brain barrier are 
monitored by non-invasively obtaining the Raman spectrum 
ofthe aqueous humor (Block 220). A physiologically suitable 
nonspecific marker, selected for its normal reluctance to 
cross the blood brain barrier, can be administered to the 
subject (Block 225), and the monitoring step can be carried 
out by identifying its presence in the selected region ofthe eye 
(typically in the AH, but the vitreous humor or “VH’may also 
be suitable in certain embodiments). The non-specific marker 
can be synthetic or natural as noted (such as an antibiotic or 
conjugated billirubin or other suitable analyte). 
The dose of the (chemotherapeutic) agent delivered to the 
brain can be estimated by determining the concentration in 
the AH (Block 230). The monitoring step can optionally be 
repeated a plurality of times during the administering step 
(Block 235). The blood brain barrier can be returned substan- 
tially to its normal state after a sufficient quantity of (chemo- 
therapeutic) agent has been delivered to the brain (Block 
240). The altering step can be carried out by administering a 
chemical which can be flushed from the system or the dosing 
terminated to allow the normal function to return. In some 
embodiments, the nonspecific marker can be the therapeutic 
agent itself. 
In one embodiment, the altering step is carried out by 
introducing an osmotic agent or chemical (such as a drug 
identified by a trade name of MANNITOL) to the subject to 
temporarily open the blood brain barrier to allow larger mol- 
ecules to pass therethrough. In another embodiment, the alter- 
ing step can be carried out by increasing the intracranial 
pressure of the subject (such as by positioning the subject in 
a pressurized chamber). 
Another embodiment is shown in FIG. 14. This embodi- 
ment is directed to a method of non-invasively monitoring the 
operatiodfunction of the blood brain barrier (which can 
include detecting any change from a normal state). The 
method comprises the steps of (a) generating an excitation 
beam at a wavelength of from 400 to 900 nanometers (Block 
250); (b) focusing the excitation beam of said generating step 
into the anterior chamber of an eye of the subject so that 
aaueous humor in the anterior chamber is illuminated (Block 
analyte of interest in the subject’s cerebral spinal fluid based 
on the detecting and comparing steps. 
FIG. 15 illustrates yet another embodiment of the present 
invention. This method for identifying an alteration in the 
blood brain barrier of a biological subject comprises the steps 
of (a) non-invasively obtaining a first in vivo Raman spec- 
trum of the aqueous humor of the subject (Block 300); (b) 
non-invasively obtaining a second invivo Raman spectrum of 
the aqueous humor of the subject (Block 310); (c) comparing 
lo the first and secondreadings (Block 320); and (d) detecting an 
alteration in the blood brain barrier (or the penetration or a 
particular drug or analyte) by comparing the first and second 
Raman spectrums (Block 330). 
In another embodiment, shown in FIG. 16, a method for 
identifying an alteration in the blood brain barrier of a bio- 
logical subject comprises the steps of (a) non-invasively 
obtaining a first in vivo Raman spectrum of the AH of the 
subject (Block 350); (b) obtaining a reference spectrum of an 
in vitro sample representing the aqueous humor and compris- 
ing at least one selected analyte (Block 360); and (c) compar- 
ing the in vivo Raman spectrum to the reference spectrum to 
identify an abnormality in the blood brain barrier (Block 
370). The abnormality may be indicated by detecting in the 
25 AH the presence of at least one selected analyte (typically one 
which is normally inhibited from passing through the blood 
brain barrier because of its molecular size or permeability 
and, as such, is not normally present in the intracranial fluid) 
thereby its presence in the AH also indicates its presence in 
The at least one selected analyte can be one which typically 
does not cross the blood brain barrier so that a determination 
of its presence in the sample is indicative of an abnormality or 
impairment or successful intentional alteration of the blood 
35 brain barrier dynamics. In one embodiment, the at least one 
selected analyte can be a bacteria. 
FIG. 17 illustrates an additional embodiment of the present 
invention. In this embodiment, a reference library of the pro- 
files of the chemical peaks (chemical peak profiles can also 
40 include the chemical vallevs or line shaoes) of the Raman 
15 . 
20 . 
3o the intracranial fluid of the subject. 
I ,  
260); (c) detecting a Raman spectrum corresponding to the spectra signals of a plurality of substances can be established 
illuminated aqueous humor (Block 270); and (d) monitoring or generated (Block 400). This can include providing the 
the blood brain barrier dynamics based on the detecting step chemical peak profiles for each of the plurality of the sub- 
(Block 280). The detected Raman spectrum can indicate stances at different concentrations. A Raman spectrum signal 
when or if a particular drug or analyte penetrates the blood 45 can be obtained in vivo of the AH (or VH) of the eye of a 
brain barrier (increases in quantity or becomes detectable) subject (Block 410). The chemical peak profile of the in vivo 
when it normally travels in the vessels andor either does not obtained Raman signal can be determined (Block 420). Next, 
penetrate the barrier or exists in a stable or predictable amount the profile of the in vivo data is compared to the reference 
in the eye (such as in the AH, VH, or vessel in the eye). The library to see if there is a statistical correlation (or best fit 
method may also include the step of exposing the subject to 50 match) between one or more of the library profiles with the in 
selected conditions during the focusing and detecting steps vivo obtained profile (Block 430). If the answer is yes, then a 
(Block 275). list of one or more substances can be generated with a percent 
In certain embodiments, the monitoring step can be used to correlation of the likelihood of the match (Block 440). The 
assess whether the dynamics thereof alter sufficiently to allow method may also rule out potential suspects (Block 441). The 
selected analytes, which would normally be inhibited from 55 list is likely to include one or more substances, as many will 
traveling through the blood brain barrier, to pass into the contain chemicals withoverlappingpeaks, but the presence or 
intracranial spinal fluid through the blood brain barrier. This absence of other peaks can help statistically fit the data to 
can be useful for clinical trials or assessments ofnew drugs or identify the closest matches. If there is no match, or the 
treatment therapies. In other embodiments, the monitoring correlation percentage is below a certain threshold (such as 
step can be carried out when a person is under or exposed to 60 below 20-50%), then the test can be identified as inconclusive 
extreme conditions such as when diving, flying, or mountain (Block 450). The method may also allow a physician to query 
climbing, or when suffering from a traumatic head or brain whether as suspect drug or substance is indicated, which may 
injury, high stress, or the like. for example, consider whether a particular “suspect” sub- 
The method can also include the steps of comparing the stance which is believed to be the ingested or consumed 
Raman spectrum from the detecting step to reference spec- 65 poison may be in the subject. In turn, the method can respond 
trums corresponding to at least one selected analyte of inter- to the inquiry to exclude the substance as a suspect with an 
est, and indirectly identifying the presence of the least one identified statistical percentage (i.e., 95% confidence level 
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that substance is not methanol) or to otherwise note the prob- 
ability of this as the poison (i.e., 5% probability that the 
substance is methanol). 
As will be appreciated by one of skill in the art, the present 
comprising a digital processing system, and/or computer pro- 
gram product. Accordingly, the present invention may take 
the form of an entirely hardware embodiment or an embodi- 
ment combining software and hardware aspects. Further- The computer Program instructions may also be loaded 
more, the present invention may include a computer program lo Onto a computer Or 0 t h  Programmable data Processing 
product on a computer-usable storage medium having com- apparatus to cause a series of operational steps to be Per- 
puter-usable program code means embodied in the medium. formed on the computer or other Programmable apparatus to 
Any suitable computer readable medium may be utilized Produce a Computer implemented Process such that the 
including hard disks, CD-ROM~, optical storage devices, or instructions which execute on the computer or other program- 
magnetic storage devices. 15 mable apparatus provide steps for implementing the fmc- 
The computer-usable or computer-readable medium may tions specified in the flowchart and/or block diagram block or 
be or include, for example, but not limited to, an electronic, 
magnetic, optical, electromagnetic, infrared, or semiconduc- b, C, FIGS. 5 and 6, the system 5 
tor system, apparatus, device, or propagation medium. More includes a signal Processor Or controller 32s. The Signal Pro- 
specific examples (a non-exhaustive list) of the computer- 2o cessor Or controller can be a general Purpose microProcessor, 
readable medium would include the following: an electrical a digital signal Processor Or a specific Purpose Processor. The 
connection having one or computer signal processor can be an electronic device, a software or 
diskette, a random access memory (RAM), a read-only Program-imPlemented device running on a general-purpose 
memory @OM), an erasable programmable read-only 25 computer, or combinations of such. The present invention 
memory (EPROM or Flash memory), an optical fiber, and a should not be construed as limited to the particular configu- 
portable disc read-only memory (CD-ROM), a CD rations illustrated in the figures but is intended to encompass 
ROM, a DVD (digital video disk), or other electronic storage 0 t h  configurations capable of carrying out the operations 
medium. Note that the computer-usable or computer-read- and/or functions described herein. 
able medium could even be paper or another suitable medium 3o The signal processor 32s can be any commercially avail- 
upon which the program is printed, as the program can be able or custom microprocessor. The computer 32 or signal 
electronically captured, via, for instance, optical scanning of processor or controller may include a data processing system 
the paper or other medium, then compiled, interpreted or with IiO data port(s) or other such devices that also commu- 
otherwise processed in a suitable manner if necessary, and nicate with the processor. The IiO data port can be used to 
then stored in a computer memory. 35 transfer information between the data processing system or 
Computer program code for carrying out operations of the Signal Processor 32s and another computer system Or a net- 
present invention may be written in an object oriented pro- work (e.g., the Internet) or to other devices controlled by the 
gramming language such as Java@, Smalltalk or C++. How- Processor. These components may be conventional Compo- 
ever, the computer program code for carrying out operations nents such as those used in many conventional data process- 
of the present invention may also be written in conventional 40 ing SYstemswhichmaY be configuredin accordance with the 
procedural programming languages, such as the “C’ or FOR- present invention to operate as described herein. 
TRAN programming language or even assembly language. The devices or the present invention may include memory 
The program code may execute entirely on the user’s com- devices containing the software and data used to implement 
puter, partly on the user’s computer, as a stand-alone software the functionality of the data processing system or signal pro- 
package, partly on the user’s computer and partly on a remote 45 cessor 32s. The memory can include both programmable and 
computer or entirely on the remote computer. In the latter read-only memory. Typical programmable memory includes, 
scenario, the remote computer may be connected to the user’s but is not limited to static RAM (SRAM), dynamic RAM 
computer through a local area network (LAN) or a wide area (DRAM), flash RAM, EEPROM or other such programmable 
network (WAN), or the connection may be made to an exter- memory devices whose contents may be modified. The read 
nal computer (for example, through the Internet using an 50 only memory may be of a type which may not be modified 
Internet Service Provider). after its initial programming, such as ROM or PROM but may 
ne present invention is described herein with reference to also be programmable in certain embodiments of the present 
flowchart illustrations and/or block diagrams of methods, invention. 
apparatus (systems) and computer program products accord- The memory may contain several categories of software 
ing to embodiments of the invention. It will be understood 55 and data used in the data processing system or system pro- 
that each block of the flowchart illustrations and/or block cessor: the operating system; the inputioutput (IiO) device 
diagrams, and combinations of blocks in the flowchart illus- drivers; and the image (and/or in the case of dual stimulus, the 
trations and/or block diagrams, can be implemented by com- auditory) data. As will be appreciated by those of skill in the 
puter program instructions. These computer program instruc- art, the operating system may be any operating system suit- 
tions may be provided to a processor of a general purpose 60 able for use with a data processing system, such as OSi2, AIX 
computer, special purpose computer, embedded processor or or OSi390 from International Business Machines Corpora- 
other programmable data processing apparatus to produce a tion, Armonk, N.Y., WindowsCE, WindowsNT, Windows95, 
machine, such that the instructions, which execute via the Windows98 or Windows2000 from Microsoft Corporation, 
processor of the computer or other programmable data pro- Redmond, Wash., PalmOS from Palm, Inc., MacOS from 
cessing apparatus, create means for implementing the func- 65 Apple Computer, UNIX or Linux, proprietary operating sys- 
tions specified in the flowchart and/or block diagram block or tems or dedicatedoperating systems, for example, for embed- 
blocks. ded data processing systems. 
These computer program instructions may also be stored in 
a computer-readable memory that can direct a computer or 
other programmable data processing apparatus to function in 
a particular manner, such that the instructions stored in the 
ture or output a test result including instruction means which 
imp1ement the 
invention may be embodied as a device, method, or system computer-readab1e memory produce an Of manufac- 
’pecified in the flowchart 
diagram Or 
As is Seen in FIGS. 
wires, a 
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The IiO device drivers typically include software routines 
accessed through the operating system to communicate with 
devices such as the input devices, the display 25 (FIG. 7), the 
IiO data port(s), and certain components of the memory. The 
data can be static and dynamic data used by the operating 
system, IiO device drivers, the detector, and other software 
programs that may reside in the memory. 
While the present invention is described, for example, with 
reference to particular divisions of programs, functions and 
memories, the present invention should not be construed as 
limited to such logical divisions. Thus, the present invention 
should not be construed as limited thereto as it is intended to 
encompass any configuration capable of carrying out the 
operations described herein. 
The present invention is explained in greater detail in the 
following non-limiting Examples, in which “pL” means 
microliters; “dL” means deciliters, “mW’ means milliwatts, 
“nm” means nanometers, “Kg” means kilograms, “J” means 
Joules, “cm2” means square centimeters, and temperatures 
are given in degrees Centigrade. 
EXAMPLE 1 
Hence, the system trains on all but one of the samples, esti- 
mates the glucose level in that sample, then rotates the test 
sample into the training set. This cycle is repeated until all 
samples have served as an unknown test sample. 
A back propagation neural network (D. Rumelhart et al., 
Nature 323, 533 (1986)) was employed to determine if a 
nonlinear regression method would better predict the glucose 
concentration from the Raman spectra of aqueous humor. 
Such a model may compensate for as yet unknown interac- 
i o  tions between analytes in aqueous humor. A two-layer back 
propagation neural network (Neuralware, Inc., Pittsburgh, 
Pa., USA) was employed using a sigmoidal function as the 
nonlinear element. Factors derived from the partial least 
squares algorithm served as the inputs to the neural network. 
15 Raw spectral data could have been used but would have 
required a prohibitively large training set. As in the linear 
regression preformed earlier, round robin training and testing 
was utilized. During training, the neural network’s weights 
were adjusted to minimize the total squared error between the 
20 actual glucose concentration and the predicted glucose con- 
centrations. Each sample was tested using a neural network 
trained on the remaining 3 1 samples. 
5 
Measurement of Aqueous Humor Glucose in vitro EXAMPLE 2 
Correlation of Aqueous Humor Glucose with Rising 
Blood Glucose 
with Raman Spectroscopy 25 
Aqueous humor was obtained from sixteen New Zealand 
white rabbits within one minute of sacrifice by other investi- 
gators. These animals had experienced experimental myocar- 
dial infarction 48 hours prior to euthanasia. They were sacri- 
ficed by rapid exsanguination under ketamine and xylazine 
anesthesia. Aqueous humor samples were kept frozen until 
glucose levels could be measured and Raman spectroscopy 
performed. Glucose concentration was measured with a com- 
mercial glucometer (Glucometer Elite, Bayer, Elkhart, Ind., 
USA) and confirmed against concentration standards. Each 
measurement was repeated, and the average measurement 
was considered actual glucose concentration. 
Nine female New Zealand white rabbits were used for this 
30 part of the study. They were anesthetized with ketamine (50 
mgkg) and xylazine (7.5 mg/kg) given as a single intramus- 
cular injection. Xylazine blocks release of insulin from the 
pancreas and causes blood glucose to rise (K. Chalabi et al., 
Ophthalmic Res. 19, 289 (1987); J. Arnbjerg et al., Oph- 
Blood samples were taken from the central ear arteries at 
various times following the injection of anesthetic once the 
animals were adeauatelv anesthetized. Whole blood was 
35 thalmic Res. 22,265 (1990)). 
u I ,  
Samples were placed in conical quartz cuvettes designed to immediately measured for glucose concentration with a com- 
hold a volume of 80 pL and permit direct optical access to the 40 mercial glucometer (Glucometer Elite, Bayer). In most 
solution by the spectrometer without traversing glass walls or instances two measurements were made. The average mea- 
coverslips. surements are reported. Ifthe measurements differed by more 
Raman spectroscopy was performed with a fil .8 holo- than 20%, a third measurement was made. If one measure- 
graphic imaging spectrograph (Kaiser Optical Systems, Ann ment differed by more than 20% from the mean, it was dis- 
Arbor, Mich., USA) attached to an Olympus BX60 micro- 45 carded. In instances when blood glucose concentration 
scope with lox objective. Data were collected using a Prin- appeared stable, occasionally only one measurement was 
ceton Instruments (Trenton, N.J., USA) camera with a 1024x made. 
256 CCD arrav (EEV. United Kingdom) cooled to -80” C. At various times after induction of anesthesia. samnles of a \  I u ,  
with liquid nitrogen. Illumination of the sample through the 
microscope objective was achieved with a Ti:Sapphire laser 
(Spectra Physics 3900S, Mountain View, Calif., USA) 
pumped by an argon laser (Spectra Physics 2010E). Spectro- 
graphic data was integrated while the sample was illuminated 
at a wavelength of 785.0 nm (30 mW) for 10 seconds. This 
illumination was then repeated at a wavelength of 787.2 nm. 
The integrated spectra at the two slightly different wave- 
lengths were then subtracted from one another. This effec- 
I I  
aqueous humor were taken. This was done by paracentesis 
50 with a 25-gauge needle through clear cornea near the limbus 
after administration of proparacaine eye drops. Aqueous 
humor glucose concentration was measured with the glucom- 
eter in a manner similar to the blood. 
In rabbits, there is massive breakdown of the blood-aque- 
55 ous barrier after a single paracentesis of the anterior chamber 
oftheeye(W.Ungeretal.,Exp.EyeRes.20,255 (1975)).The 
aaueous humor becomes too viscous for reneat naracentesis u I I  
tively eliminates the broadband fluorescence, which does not for at least 30 minutes. Consequently, the results are reported 
shift relative to the excitation wavelength. It leaves the for the first paracentesis of an eye. In a few instances, how- 
Raman-shifted spectra appearing as a bipolar pattern (FIG. 60 ever, a second paracentesis was made an hour later to assess 
1). how the breakdown of the blood-aqueous barrier may have 
Multivariate analysis of the spectra was accomplished affected the correlation of aqueous glucose with plasma glu- 
using Holograms (Princeton Instruments, Trenton, N.J.) and cose. 
Grams (Galactic Industries, Salem, N.H. USA) software Average blood glucose concentrations for each animal 
packages. Thirty-two aqueous humor samples (from sixteen 65 were plotted against time after anesthetic injection. Since it 
rabbits) were evaluated using a “round robin” approach to was not possible to obtain blood samples simultaneous with 
iteratively group all but one of the samples into a training set. aqueous humor samples, a best-fit second-order polynomial 
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These data also demonstrate that aqueous humor glucose in 
the rabbit responds almost immediately once blood glucose 
exceeds 200 mgidL. The relationship of aqueous humor glu- 
cose to blood glucose is nearly linear while blood glucose is 
5 rising above 200 mgidL. Below that level, aqueous humor 
glucose appears stable. What happens to aqueous humor glu- 
cose when blood glucose is clamped at a hyperglycemic level, 
or when blood glucose concentration drops, has yet to be 
determined. Nonetheless, equilibration of aqueous humor 
i o  glucose with blood glucose probably occurs within minutes 
in rabbits. If rapid equilibration of aqueous humor glucose 
also occurs in humans, it could serve as an excellent substrate 
was calculated for each animal. This was used to calculate the 
blood glucose concentration at the time that the aqueous 
humor sample was taken. Aqueous humor glucose concen- 
tration was then plotted against the calculated simultaneous 
blood glucose concentration for all animals. DeltaGraph soft- 
ware (Delta Point, Inc., Monterey, Calif. USA) was used for 
all statistical calculations. 
EXAMPLE 3 
Results for Measurement of Aqueous Humor 
Glucose In Vitro With Raman Spectroscopy 
The raw spectra of rabbit aqueous humor show broad fluo- 
rescence peaks that obscure the underlying Raman signature 
(FIG. 1). When the spectra from the two slightly different 
wavelengths are subtracted, one from the other, the Raman 
shifted spectra become apparent as bipolar peaks. 
Actual aqueous humor glucose concentration, measured 
by the glucometer, ranged from 37 to 323 mgidL in the 
thirty-two samples. Multivariate analysis of the raw spectra 
from these samples with the partial least squares algorithm 
revealed fair correlation (r’sO.76) between the predicted 
aqueous humor glucose concentration and the actual concen- 
tration. Multivariate analysis of the subtracted spectra from 
these samples with the partial least squares algorithm resulted 
in improved correlation (r2=0.90) between the predicted 
aqueous humor glucose concentration and the actual concen- 
tration. When back propagation with an artificial neural net- 
work is further applied to the data, correlation is excellent 
(?=0.98) (FIG. 2). 
for non-invasive glucose monitoring. 
Previous investigators have found no breakdown in the 
blood-aqueous barrier of albino rabbits exposed to infrared 
radiation with energy densities up to 106 Jicm (D. Reddy, 
supra; G. Peyman et al., Exp. Eye Res. 42, 249 (1986); T. 
Kurnik et al., Znv. Ophthalmol. Vis. Sci. 30, 717 (1989)). 
Infrared energy densities as low as 44 Jicm’ may be sufficient 
to breakdown the blood-aqueous barrier inpigmentedrabbits, 
however. This is still substantially higher than the energy 
density that would need be applied with the Raman technique 
disclosed herein. 
FIGS. 21A-C illustrate experimental results obtained for 
(a) the spectrum for an artificial in vitro AH in a model 
anterior chamber (FIG. 21A); (b) the spectrum for an actual in 
vitro measured (extracted real AH) in a model anterior cham- 
ber (FIGS. 21B); and(c) thespectrum foranactual invivoAH 
measurements (FIG. 21C). A 20x objective with a numerical 
aperture of about 0.4 was used to obtain the data. The 
“ensemble” spectra (of the constituents of the AH) corre- 
spondwell between the three figures. As may be expected, the 
in vivo and in vitro intensity of the Raman spectra was less 
than the in vitro artificial sample, but the spectra peaks cor- 
35 responded well between the measurements (the device able to 
detect the physiological levels). The invitro measurements of 
the AH were obtained using extracted rabbit eyes placed 
under a contact lens. 
EXAMPLE 4 
Results for Correlation of Aqueous Humor Glucose 
with Rising Blood Glucose 
The rate of rise of blood glucose after xylazine injection is 
highly variable from animal to animal (FIG. 3). In fact, in one 
rabbit there was little change in the blood glucose concentra- 
tion over time. 40 EXAMPLE 5 
If only samples taken in the first fifteen minutes after anes- 
thetic injection are considered, aqueous humor glucose con- 
centration is higher than blood glucose concentration Blood-Brain Barriers 
(207228 mg/dL for aqueous humor; 135227 mgidL for 
blood). When calculated blood glucose rises above 200 45 The blood-brain and blood-aqueous barriers block passage 
mgidL, simultaneous aqueous humor glucose parallels blood of large molecules into the cerebrospinal fluid or aqueous 
glucose nearly linearly [aqueous humor glucosesl. 18 (blood humor. Many drugs and disease processes result in disruption 
glucose)-72.7; ?=0.88] (FIG. 4). of both the blood-aqueous barrier and the blood-brain barrier. 
The number of aqueous humor samples from second para- In the case of such drugs or disease processes, disruption of 
centeses was insufficient to draw conclusions about their 50 the blood-brain barrier can be inferred from breakdown ofthe 
significance. They did not appear, however, to correlate well blood-aqueous barrier. Breakdown of the blood-aqueous bar- 
with aqueous humor glucose levels from initial paracenteses rier can be measured by measuring the protein content of the 
(FIG. 4). aqueous humor or by measuring the concentration of other 
These data indicate that the baseline ratio of aqueous substances (e.g., drugs) within the aqueous humor. Such sub- 
humor glucose to blood glucose in rabbits is approximately 55 stances may be quantifiable by Raman spectroscopy and the 
1.5. (It may actually be higher than this as a true baseline was protein can be calculated from the fluorescence spectrum 
not obtained, and the blood glucose levels were likely since the fluorescence spectrum is largely generated by pro- 
elevated by the time the first samples were obtained, even in tein. Consequently, the devices disclosed herein for measur- 
the first 15 minutes after injection.) This is much higher than ing glucose and other Raman scattering metabolites in the eye 
in humans and higher than in previous reports on rabbits. All 60 can be used for measuring the integrity of the blood-aqueous 
previous reports on rabbits, however, were prior to recogni- and blood-brain barriers. 
tion of the hyperglycemic effect of xylazine anesthesia, yet Raman scattering molecules of different sizes that do not 
many of them used xylazine anesthesia. In addition, most normally cross the blood-aqueous or blood-brain barrier 
previous reports assumed that the rabbits were at steady-state could be administered to a patient intravenously. The pres- 
euglycemia, without actually confirming that this was the 65 ence of these molecules is then identified and/or quantified by 
case. These facts may account for some ofthe highly variable Raman spectroscopy of the anterior chamber of the eye. This 
results in previous reports. can be used to determine the size of molecules which pass 
Measurement of the Integrity of Blood-Aqueous and 
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through the blood aqueous barrier. The signature of the 
Raman spectroscopy signal can then digitally be compared to 
reference signals (without requiring the use of a difference 
methodology which would subtract the amount of fluores- 
cence to reveal the Raman spectra of these substances) with 
the device disclosed herein would reflect the passage of natu- 
ral proteins through the blood-aqueous and blood brain bar- 
riers. 
Therapeutic drugs can also be measured to determine their 
effectiveness in crossing the blood-aqueous or blood-brain 
barrier or to determine if a drug has undesirable passed there- 
through. 
EXAMPLE 6 
Monitoring the Blood Brain Barrier During a 
Treatment Session 
A patient undergoing treatment for a cancer located in the 
brain or on the other side of the blood brain barrier is admin- 
istered a nonspecific marker which is configured such that it 
does not normally cross the blood brain barrier (or is reluctant 
to do so) and which is relatively easily detectable when in the 
AH by the use of Raman spectroscopic analysis. The blood 
brain barrier can be altered by administering an osmotic agent 
such as a chemical substance (such as a drug identified by the 
trade name "MANNITOL" or a similar substance) which acts 
to physiologically alter the blood brain barrier. In so doing, 
the blood-aqueous barrier is also altered. In turn, the non- 
specific marker travels to the AH. An optical measurement 
can be obtained to confirm that the nonspecific marker is 
indeed in the AH (in a sufficient or elevated quantity to indi- 
cate that the blood-aqueous barrier has been altered). The 
present invention, recognizing that the mechanics of the 
blood-aqueous barrier and the blood-brain barrier are similar, 
then presumes that the blood brain barrier has also been 
altered sufficiently (scale correlation factors may be applied 
to assure that the blood brain barrier is openedaltered a 
sufficient amount). 
A therapeutic drug (which may be a chemotherapy or cyto- 
toxic drug) can then be administered (injected or otherwise 
delivered) to the subject. Administering the therapeutic drug 
after the barrier has been altered can help ensure that the 
therapeutic drug is not introduced until the blood-brain bar- 
rier is altered sufficiently and can allow an elevated amount of 
the therapeutic drug to pass through the blood-brain barrier 
over a non-altered state. This can facilitate that more of the 
drug goes where it is targeted and can reduce the amount in 
the system of the subject which can often be exposed to 
undesirable amounts of cytotoxic drugs in conventional treat- 
ments in order to ensure that a sufficient amount actually 
reaches the tumor. 
Thus, the present invention now allows one to intentionally 
break down the barrier and non-invasively confirm the alter- 
ation before delivering medicines, which do not normally 
readily cross the blood brain barrier, to tumors and the like 
positioned in the blood aqueous or blood brain barrier. Cor- 
relations of the amount of the drug administered to the sub- 
ject, to the amount of the marker administered and detected in 
the AH, may be established to allow an estimate ofthe amount 
of the drug in the spinal fluid or in the blood. Thus, the present 
inventionmay also be able to titrate the dose so that the levels 
in the spinal fluid are sufficiently high but not toxic to the 
patient in non-targeted regions of the body. 
42 
EXAMPLE 7 
Measurement of Brain Alcohol Level 
5 Aportable device can be used to hold the optical generation 
and measurement system. The device can be readily carried 
by police enforcement agencies and conveniently used when 
a suspect is evaluated for potential DUI infractions. Thus, the 
device can be positioned over the eye(s) of the subject and the 
i o  subject can be instructed to read or identify the text or object 
encoded or displayed as the fixation target in the headset over 
the eye or eyes. When the subject verbally affirms the proper 
identification of the fixation target, the device can be operated 
to obtain a reading. The device may include an auto or manual 
15 focus to correct the vision in the device and to allow the 
subject to focus to the target as needed. Almost instanta- 
neously, the police officer can have quantitative results of the 
brain alcohol or blood alcohol level of the suspect. The 
amount or concentration of the alcohol determined to be in the 
20 AH (or conjunctiva vessel) can be correlated to either a blood 
alcohol andor brain alcohol level. Many states presently 
regulate bloodalcohol levels; however, it is anticipatedthat an 
impairment can be assessed also basedon either or both blood 
or brain alcohol levels. As such, the device may generate a 
25 plurality of numbers, such as the concentration in the eye, 
and, the indirectly measured or correlated concentration in 
the blood andor brain. If above the legal limit, which can be 
programmed for each state or locality, a documentary arrest 
record can be generated with a date and time stamp encoded 
30 onto the measurement record that can be automatically gen- 
erated and electronically stored or printed. 
In some embodiments, the Raman spectrum of the subject 
may include many wavelengths and the determination of the 
concentration or presence of alcohol may include determin- 
35 ing the significant peaks associated with alcohol and subtract- 
ing the AH constituents from the signal. It is anticipated that 
the method and devices will be able to identify blood alcohol 
and brain alcohol levels between about 0.001-1%, and typi- 
cally between 0.01 -0.8% (noting that concentrations above 
40 1% may be lethal) and that medical assistance may be indi- 
cated for certain levels. 
EXAMPLE 8 
45 Non-invasive In Vivo Identification of the Presence 
of Illegal Narcotics 
Aportable device can be used to hold the optical generation 
and measurement system. The device can be readily carried 
50 by state or federal police enforcement agencies (or hospitals 
including medical examiners for autopsy) and conveniently 
used when a suspect is evaluated for potential illegal posses- 
sion of drugs. In operation, the device can be configured as a 
headset with the display and light transmission path posi- 
55 tioned in front of the eye(s) of the subject. The subject can be 
instructed to read or identify the text or object encoded or 
displayed in the device as the fixation target in the headset 
over the eye or eyes. The device may include an auto or 
manual focus to correct the vision in the device and to allow 
60 the subject to focus to the target as needed. When the subject 
verbally affirms the proper identification ofthe fixation target, 
the device can be operated to obtain a reading. Almost instan- 
taneously, the police officer can have quantitative results of 
whether the suspect has inhaled, ingested, injected, or other- 
65 wise consumed an illegal narcotic. It is anticipated that con- 
centrations in the range of between about 0.001-1% (in the 
AH) or higher in the conjunctiva vessel (Le., in the blood 
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volume) may be quantified. Drugs present in small quantities ing the data associated therewith in an electronic poison con- 
(such as the picomolar range) may be able to be identified (or trol reference library, the methods and devices of the present 
the bodies’ reaction thereto identified thereby identifying the invention can deconvolute the in situ obtained Raman spec- 
drug) but may not be able to be reliably quantified. trum signal to build or match a signal pattern with the Raman 
It is noted that illegal narcotics may vary jurisdiction to 5 reference standards. Based upon the substances with signa- 
jurisdiction and the device can be programmed according to tures, which substantially match the in situ Raman signal, 
the laws of the jurisdiction of use. Examples of illegal nar- probable or possible substances can be identified (or to 
cotics include opiate-based drugs such as cocaine in several exclude other suspect substances). Knowing which of the 
forms such as crack, powder, and the like, and other drugs chemicals or substances have the profile signature closest to 
such as LSD, pcp, angel dust, marijuana, and others. It is i o  the in situ obtained signature, the Raman signal(s) allows for 
anticipated that the most commonly used or street available the identification of which poisons may be in the body. The 
illegal drugs or abused prescription drugs can be analyzed to match can be based on a computational comparison of peaks 
predetermine the Raman signature as discussed above and or a graphical comparison. For example, the match can be 
these reference signature standards for these substances carried out by matching the peaks or line shape profile across 
stored for reference to the in situ reading obtained on the 15 the spectrum of interest via best-fit curves or statistical cor- 
suspect. relation methods can identify products which align or match 
Incertainembodiments, the device andmethodcaninclude that of the data from the subject. A list of substances with 
assessing both, the brain alcohol (or blood alcohol) level of associatedprobability ratings can be provided to the clinician. 
the suspect, and the presence of an illegal narcotic with one In addition, a quantitative determination of the amount of 
reading. Further, the present invention can be used to develop 20 the identified substance or substances in the body may be able 
legal limits for other non-alcohol products so as to ascertain to be made depending on the strength of the signal (stronger 
whether an individual is impaired for improved safety on the signals typically indicate higher concentrations). 
roadways. In one embodiment, the Raman signature of a selected 
If an illegal narcotic is identified or if the alcohol level is metabolite can be reviewed to see if the level is carcinogenic 
above the legal limit, (the legal limit can be programmed for 25 in the subject. For example, antifreeze (ethylene glycol) can 
each state or locality), a documentary arrest record can be be toxic to the liver. If it is identified that the either ethylene 
generated with a date and time stamp encoded onto the mea- glycol was ingested or that the liver is emitting toxins or 
surement record which can be automatically generated and products, a treatment such as alcohol can be administered to 
electronically stored or printed. offset the toxicity of the poison. Similarly, for other embodi- 
30 ments, the substance or drug itself may not be detectable in 
minute quantities in the body (typically in the pic0 or micro 
molar range). However, it may be possible to detect either a 
constituent of the substance of interest, or a physiologic reac- 
tion to the substance, to see if it is in an elevated level in the 
35 body (due to the body breaking down or reacting to the 
substance). 
EXAMPLE 9 
Determination andor Identification of Drug or 
Steroid Use 
In lieu of conventional urine tests, the present invention can 
be used to screen potential employees for drug use, or to 
assure employees are drug or alcohol free prior to allowing 
them to operate equipment (such as airplanes, trains, buses, 
subways, or other mass transit systems or heavy equipment 40 
and the like). This convenient and non-invasive screening 
may be a suitable testing system to help assure that the opera- 
tors entrusted with the lives of others are not operating in an 
impaired state. In certain embodiments, the excitation wavelength of the 
The present inventioncan also beused to screen athletes for 45 substance of interest is selected so that it amplifies the detect- 
banned substances prior to competitions or at periodic or able RR response signal or spectra. The excitation wave- 
audit intervals, andor to screen parolees for violation of length is selected so that it lies within or proximate to the 
parole. Indeed, the readings can be obtained locally and then absorption spectrum of the selected substance. The RR spec- 
electronically relayed to a remote monitoring station where tra is typically generated by a wavelength that resides within 
the results can be analyzed and proper authorities alerted of a 50 the absorption spectrum (and above 400 m ) . A s  noted above, 
positive test. the term “resonant Raman” includes non-resonant excitation 
wavelengths approaching the absorption spectrum that can be 
used to generate spectra with increased signal strength (such 
as signal strengths having 100-1000 times or more signal 
55 intensity strength relative to excitation wavelengths that sub- 
stantially depart from the wavelengths associated with the RR 
Similar to Example 8, an in situ reading can be taken on an spectra). One or more peaks of interest in the RR or Raman 
initial evaluation of a poison suspect, either by a paramedic at spectra can be monitored to identify the presence andor 
a home or in route to a hospital, or by a clinician, such as at an quantity of the substance in the subject. In particular embodi- 
Emergency Room, to allow a relatively fast triage assessment 60 ments, a chemical shift peak associated with a double carbon 
of whether one or more poisons are present in the body. One bond may be monitored. 
reading may be able to identify one or more of several differ- In certain embodiments, one or a plurality of selected seg- 
ent signature peaks associated with several different poisons. ments (typically relatively narrow regions of less than about 
The poisons may be common household products such as 200 cm-’, and more typically less than about 100 cm-’ in 
different medications, or a pesticideherbicide, a cleaning 65 width) in the Raman spectrum can be used to determine the 
agent, or antifreeze. By pre-evaluating the Raman signature concentration levels in a subject. The regions used to assess 
of a plurality of common substances and electronically stor- concentration can be selected so as to exclude regions that are 
EXAMPLE 11 
Identifying a Pre-determined Substance Using 
Resonant or Strongly Pre-resonant Raman Spectra 
andor Double Bond Peaks in the Raman Spectrum 
EXAMPLE 10 
Identification of Ingested Poison(s) 
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associated with spectral shift that may occur at increased agent. This agent is a broad-spectrum antifungal agent used to 
concentration levels to thereby provide reliable concentration treat potentially fatal fungal infections of the CNS. It has a 
data over a broader in vivo range of probable bio-concentra- molecular weight of 924.1. 
tions. FIG. 28 is a graph of the absorption spectrum of amphot- 
FIG. 22A illustrates the chemical structure of a chemo- 5 ericin B at a concentration of 5 pgiml. 
therapeutic agent known as fenretinide (4-HPR), and shows a FIG. 29 is a graph of the RR spectrum of (generated at an 
conjugated chain structure portion of the structure that per- excitation wavelength of 406.7 nm) of amphotericin at three 
mits resonance enhancement. Note that even at 10-micromo- different concentrations (mixed in MeOH): 5.0 pgiml, 0.5 
lar concentration the solution has a yellow color. This can be pglml, and 0.05 pgiml. Characteristic peaks of amphotericin 
important because the concentration may be such that the i o  can be detected by Resonant Raman (RR) spectroscopy (406 
drug can block the penetration of the excitation light and nm) at concentrations as low as 0.05 microgramsiml (and 
limits the Raman scattering (e.g., see FIG. 26). Typically, at potentially much lower). The therapeutic level of amphoteri- 
lower concentrations this is not a problem. cin is about 0.5-5.0 microgramsiml. 
FIG. 23 is a graph of the absorption spectrum of fenretin- 
ide, illustrating that the absorption peaks at 365 nm. Exciting 15 
the molecule at 406.7 nm enhances the signal such that most 
of Raman shifted scattered light is not absorbed by the mol- 
ecule itself, and so that undesirable excitation or exposure 
wavelengths are avoided (such as those below e400 nm). 
Raman-based instruments and information processing 
versus wavelength shift of a non-resonant Raman spectres- capability can be used to non-invasively measure ethanol 
copy (using an excitation wavelength of 785 nm) of fenretin- and/or its metabolites in the human aqueous humor. 
ide (concentration 10 mM, dissolved in ethanol). The spec- It is anticipated that the ability to measure ethanol non- 
trum shows key peaks offenretinide as distinct from those of invasively may revolutionize the treatment and study of alco- 
ethanol (ETOH Peak at 8x1 cm-'). Particularpeaks ofinterest 25 holism. Conventional techniques that measure ethanol by 
for the fenretinide one Or more ofwhichmay be monitored (or electrochemical, enzymatic, or colorimetric techniques in the 
the entire profile) include the peak at 1 17 1 cm-' (correspond- breath, urine, or excreted body fluids are generally considered 
ing to the carbon-carbon bond) in the molecular structure and intrusive, unreliable, or subject to user non-compliance. 
the peak at 1576 cm-' (corresponding to the carbon to carbon Spectroscopic techniques have been proposed in the past, but 
(double bond)) in the molecular structure. 30 the techniques remain elusive. See, e.g., Marose S, Linde- 
FIG. 25A is a graph of the absorption spectrum (absorption mann C, Ulber R, Scheper T. Optical sensor systems for  
versus wavelength) of a solution of 10 mM of fenretinide. bioprocess monitoring, Trends in Biotechnology 17: 30-34, 
FIG. 25A is inset within FIG. 25B, which is a graph of 1999. 
pre-resonant (excitation wavelengths above the resonant In pilot studies undertaken in connection with the present 
wavelength) spectra of a 10 mM fenretinide corresponding to 35 invention, a correlation of ethanol concentration predicted by 
the substance with the absorption spectrum shown in FIG. Raman spectroscopy with actual ethanol concentration in 
25A. As shown, the intensity is normalized to the ETOH aqueous solution at levels typically found in blood following 
signal (arbitrary units), but the data need not be adjusted in alcohol consumption has been demonstrated. Metabolites of 
EXAMPLE 12 
Non-Invasive Ethanol Monitoring Using Raman 
Spectroscopy 
FIG. 24 is a graph of the Raman spectrum of intensity 20 
this manner. Three different excitation wavelengths are ethanol, such as acetaldehyde and acetate, may be measured 
shown, the signal strength increasing for a decreasing wave- 40 non-invasively, allowing for the added benefit of studying 
length. That is, the spectra corresponding to the 514 nm alcohol metabolism. 
excitation wavelength has a larger signal intensity than the In the past, non-invasive spectroscopic detection of alcohol 
spectra corresponding to either the 633 nm or 785 nm wave- has been problematic because blood, tissue, and most 
lent@,. As shown, the intensity values ofthe peaks at 1576 excreted fluids contain numerous substances that confound 
cm- and 1 171 cm-' are increasedrelativeto thepeaks at these 45 ethanol spectral signatures. Appropriate selection of sources 
positions in the Raman spectra for the 785 nm or 633 nm or techniques for spectroscopic analysis can inhibit or sup- 
excitation wavelengths. Accordingly, FIG. 25B demonstrates press these confounding signatures. One suitable monitoring 
that Raman sensitivity increases as the excitation wavelength siteisource is the aqueous humor (AH) filling the anterior 
approaches the absorption spectrum of a particular molecule chamber of the eye (between the lens and cornea). The AH 
or substance (shown for illustrative purposes as fenretinide, 50 contains relatively few molecules (such as proteins) capable 
that devices can be configured to operate above resonance primary constituents of AH are glucose, lactate, ascorbate, 
wavelengths (outside the absorption spectrum or curve) and urea. Accurate and reliable measurement of these 
be particularly suitable for detection of the peaks due to 55 spectroscopy using reasonably low power levels as described 
carbon double bonds that occur even for chemicals that do not in the specification above in more detail. 
resonate or for which resonant Raman spectroscopy would be Furthermore, as with cerebrospinal fluid, AH can be sub- 
difficult. stantially freely permeable to ethanol. This fact and its opti- 
FIG. 26 is a graph of resonant Raman (RR) spectra of cally accessible location, make AH a suitable choice as a site 
fenretinide generated at an excitation wavelength of about 60 for non-invasive analysis of ethanol. 
406.7 nm. The peaks for fenretinide 117licm and 1576icm In addition, Raman Ethanol Assay (REA) of the aqueous 
can be detected at concentrations as low as 0.1 micromoles. humor can be obtained by or linked to a dual-purpose device 
The peaks (S) from the solvent, ethanol, are diminished at the that can also perform as an identify-verification device that 
higher fenretinide concentrations due to the absorption of identifies individuals based on an image analysis of retinal or 
excitation light by the fenretinide itself. 65 iris architecture. Examples ofbiometric evaluations ofthe eye 
FIG. 27 is a drawing of the chemical conjugated structure using retinal or iris structures include U.S. Pat. Nos. 5,291, 
ofamphotericinB (C,,, H,,, NO,,), anexemplary antifungal 560; 6,119,096; 5,615,277; 5,613,012; 5,572,596; 5,471,203; 
even at pre-resonance wavelengths). This may be useful in of interfering with the spectroscopic detection of ethanol. The 
although approaching absorption spectrum values and may metabolites at physiologic levels is possible with Raman 
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5,336,970; the contents of these patents are hereby incorpo- 
rated by reference as if recited in full herein. Such dual- 
purpose devices can be used for public safety or security 
purposes (such as analysis of drivers, pilots, operators or 
workers in certain high-risk or public safety industries or for 
verifying the identify of an athlete, parolee, and the like) or 
where otherwise appropriate. One manufacturer of iris-based 
biometric devices is IriScan, Inc., located in Mt. Laurel, N.J. 
The present invention can be embodied in portable devices 
that can obtain the signals from the eye(s) of a subject (for 
AH) sampling at desired field locations. For example, the 
image or signal acquisition can be carried out with a minia- 
turized device such as one that can be attached to headgear or 
face gear such as spectacles, goggles, face-mask, or a contact 
lens device. The signal acquisition device that generates the 
REA ofthe aqueous humor can be operated in an intermittent, 
semi-continuous, or even potentially in a low power continu- 
ous manner. REA of the aqueous humor has an advantage of 
being operable in a completely non-invasive manner. As such, 
it may be operated as a technique for intermittent rapid deter- 
mination of ethanol alcohol levels at a particular point or 
points in time or as a longer-term monitoring technique that 
collects data over a desired monitoring period of hours, days, 
or, even months. The data can be collected and analyzed by 
the (preferably portable) device itself or stored and telemetri- 
cally or periodically downloaded to a remote analysis system. 
In certain embodiments, one or a plurality of selected seg- 
ments (typically relatively narrow regions of less than about 
200 cm-', and in certain embodiments less than about 100 
cm-' in width) in the Raman spectrum can be used to deter- 
mine the ethanol concentration levels in a subject. The 
regions used to assess concentration can be selected so as to 
exclude regions that are associated with spectral shift that 
may occur at increased concentration levels to thereby pro- 
vide reliable concentration data over a broader in vivo range 
of probable bio-concentrations. 
Exemplary Raman Instrument for Spectral 
Measurements of AH 
The REA of aqueous humor can utilize an existing fil.8 
Kaiser Optical Systems holographic imaging spectrograph 
which is fiber-optically coupled to a probe head that is con- 
figured to detect in a continuous or intermittent manner. The 
probe head may be handheld, or mounted on a translation 
stage for studying sedated animals. In the past, a 20x objec- 
tive was used to acquire spectra of 50-100 uL samples of 
rabbit aqueous humor with excellent results in measurement 
of glucose, lactate, and urea. See Borchert et al, A non-inva- 
siveglucose monitor: Prelimina y results in rabbits, Diabetes 
Tech. and Therapeutics. 2:141-151, 1999. An existing exter- 
nal cavity diode laser manufactured by SDL can be utilized as 
the excitation source. An excitation wavelength of 785 nm 
may be selected because it is barely visible to the subject and 
provides a comfortable fixation target as well as a source 
which may be used in a minimally or non-intrusive continu- 
ous monitoring device. Near-infrared excitation also greatly 
reduces the background fluorescence from the eye as well as 
from minor constituents within the aqueous humor. However, 
Raman scattering efficiency decreases inversely with wave- 
length to the fourth power. This decrease in Raman signal 
associated with near-infrared excitation can be compensated 
by using a liquid nitrogen cooled, thick-epitaxial, deep deple- 
tion CCD detector with high or extremely high quantum 
efficiency in the 700-1000 nm wavelength range (typically 
about 785 nm). Since the silicon CCD becomes increasing 
transparent in the NIR, a thick-epitaxial design can reduce the 
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effects from etaloning. The REA system can employ a con- 
focal configuration for the eye, which allows for selective 
collection of spectra from the aqueous humor of the eye, as 
well as for monitoring of centration of the beam. 
A diagram of examplary probe head architecture is shown 
in FIG. 6. As shown, the probe-head design incorporates a 
single-mode excitation fiber and a step-index multi-mode 
collection fiber. The probe-head objective images the focal 
point to the multi-mode collection fiber. A 50 micron chrome 
aperture was evaporated onto the end of collection fiber to 
adjust the confocality of the probe head to collect as much 
Raman scattered light from within the anterior chamber as 
possible while rejecting light from the cornea or lens of the 
15 eye. A system configured in this manner was tested for its 
ability to collect the spectra of saline by placing this solution 
under a contact lens resting on a quartz plate. The signature of 
the contact lens, saline, and quartz plate could each be iso- 
lated by focusing on each element of this physical model of 
20 the anterior chamber. This experiment was repeated on the 
eye of a living rabbit and similar results were obtained. See 
Lambert et al., Measurement ofAqueous Glucose in a Model 
Anterior Chamber Using Raman Spectroscopy, Jnl. Of 
Raman Spectroscopy (In Press, 2002). Spectra for both 
FIG. 31A illustrates the Raman spectra of artificial aqueous 
humor (AAH) and components of a physical model of the 
anterior chamber collected using confocal optics. FIG. 31B 
3o illustrates the in vivo Raman spectra of structures of the 
anterior chamber of a rabbit. Raman spectra ofAH can clearly 
be distinguished from those of nearby cornea and lens. 
Mathematical Models for Calculating Analyte Concentration 
A variety of chemometric methods have been developed to 
derive quantitative information from the spectrum of an aque- 
ous test sample having a mixture of constituents. In general, 
chemometric models are developed using Raman spectra 
40 acquired from a set of training samples where the concentra- 
tion of one or more of the constituents in each sample is 
known. Calibration models are developed and subsequently 
used to predict the concentrations of the constituents within 
sample unknowns for which these models were developed. A 
45 summary of the commonly used linear methods is presented 
below. Review articles are available which discuss these 
methods in detail. See, e.g., Geladi et al., Partial least squares 
regression: A tutorial, Analytica Chimica Acta. 1986, 185: 
1-17; and Haaland et al., Partial least squares methods fo r  
50 spectral analysis. Relation to other quantitative calibration 
methods and the extraction of qualitative information, Anal. 
Chem. 1988: 60; 1193-1210. 
The vast calibration models developed to date are linear 
and therefore implicitly assume that the Beer-Lambert law is 
55 valid for the samples being utilized on the training or test set. 
The Beer-Lambert law states that there must be a linear rela- 
tionship between the concentrations of the constituents and 
the amount of Raman light scattered at a given wavelength 
from each constituent. For any given sample the observed 
60 Raman signature is a linear combination of the spectra of its 
constituents. The Beer-Lambert law may not be valid when 
constituents react with each other or when they interact with 
the solvent. For example, some of the Raman peaks for etha- 
nol in aqueous solution shift as the concentration of ethanol is 
65 increased. However, at concentrations in the range of interest 
(typically between about 5-500 mgidL), this effect is smaller 
than the resolution of most Raman instruments (5 cm-'). 
25 experiments are shown in FIGS. 31A and 31B. 
35 from Measured Spectra 
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Even for relatively high concentrations of ethanol, selected models are likely to perform well in predicting certain sub- 
regions of the spectra in which the spectral shifts occur may stances, such as, but not limited to, ethanol, in physiological 
be excluded from analysis to maintain the validity of the fluids. PLS can be extended to solve for additional analytes by 
linear model. applying it separately for each analyte of interest. HLA may 
Alternatively, a piecewise linear calibration model can be 5 be extendable algorithmically to include multiple pure spec- 
developed over several concentration ranges, where the Beer- tra (e.g. ethanol, acetaldehyde, and acetate) within an 
Lambert law remains valid over each range. Generally stated, enhanced calibration model for the analysis of complex mix- 
linear chemometric methods can be divided into two types of tures. 
algorithms: explicit and implicit methods. Explicit methods Notwithstanding the above, as before, on certain embodi- 
are mathematical models that employ knowledge of the spec- 10 ments, the model can analyze one, and typically a plurality of 
tra of every constituent. Explicit methods include linear selected segments (typically relatively narrow regions of less 
regression, classical least squares (CLS) and ordinary least than about 200 cm-', and more typically less than about 100 
squares (OLS). These methods are generally capable of pro- cm-' in width) in the Raman spectrum can to determine the 
ducing superior calibrationmodels. However, significant per- concentration levels in a subject. The regions used to assess 
formance degradation can occur if a constituent is omitted 15 concentration can be selected so as to exclude regions that are 
from the calibration model or in the presence of spectral associated with spectral shift that may occur at increased 
artifacts such as baseline shifts. Employing explicit methods concentration levels to thereby provide reliable concentration 
in complex biological fluids such as aqueous humor can be data over a broader in vivo range of probable bio-concentra- 
difficult in general, since many constituents may be involved. tions. 
To generate a reliable calibration model using these tech- 20 
niques, a chemical assay and every in the InVitro Raman EthanolAssay of"Artificial"Aqueous Humor 
training set should be used. If the constituents in the training aqueous humor were prepared 
set are not completely known, errors in the solution of the with PhYSiologic levels of glucose (97 mgidl), ascorbate (16 
model may result. mgidl), lactate (84 mgidl), and urea (36 mg.dl) in normal 
utilize information only from the con- 25 saline. Ethanol was added to these samples to achieve a final 
Fifteen Of 
~ ~ ~ l i ~ i ~  
stituent of interest. These methods do not deduce any of the 
pure spectra present within a test sample. They can compute 
sample directly from information derived from a training set 
constituent of interest. Care should be taken in developing 
implicit calibrationmodels to ensure that other constituents in 
concentration ranging from to 0.5%. Raman spectra 
were acquired for each Of the in quartz cuvettes. 
the Kaiser 785 nm spectrometer. The incident Power Of l5 
sample was normalized by dividing each spectra by the area 
Of the bonding region in the 400-600 cm-' range. 
the concentration of the constituent of interest within the test 
ofmixture spectra withaknownvalueofconcentrationforthe 30 mW for 2o seconds was 
Raman spectra Of each were using 
The spectrum Of each 
the training set are not collinearly related to the constituent of spectrum was then subtracted from a spectrum 
interest. Partial least squares (PLS) and principal component Of aqueous humor with O% 32). 
analysis (PCA) followed by principal component regression 35 A PLS training m d e l  was developed using 10 Raman 
(PCR) are well known implicit that can be used in spectra collected for each of 15 samples. The eleventh spectra 
calibration to provide good performance in the collected for each sample was treated as an "unknown"and its 
assessment of ethanol andor its metabolites or other analyte concentration was Predicted Using the PLS training mde l .  
of interest in applications evaluating a selected region of the Using only two factors in this model, the &~ndard m o r  of 
eye. PLS and PCR calibration models employ a set of mixture 40 Prediction (SEP) was 23 m!d& and the co~relation coeffi- 
spectra fromtypical samples of the fluid of interest along with cient (R2) was 0.99935.AdditionallY, all samples were incor- 
the concentration of the constituent of interest. porated into a PLS model and testedusing cross-validation by 
Knowledge of the pure spectra of the constituent(s) of using a leave-one-out round robin approach. The Standard 
interest, particularly ethanol andor its metabolites, is error of cross-validation (SECV) and correlation coefficient 
tively easily obtained. However, the implicit methods dis- 45 were 0.019 WidL and 0.9991, respectively. Predicted @a- 
cussed above may not be able to incorporate this information manmeasured) vs. actual ethanol concentrations are shownin 
in their calibration models. The explicit models can incorpo- FIG. 33. 
rate the information, but spectral information from a plethora FIG. 32 illustrates normalized spectra for various levels of 
of other possible contaminants may make implementation ethanol in artificial aqueous humor at wave numbers ranging 
difficult. Andrew Berger recently developed a methodknown 50 from 700-1700 cm-' and amplitude (in arbitrary units). FIG. 
as hybrid linear analysis (HLA), which has been shown to 32 shows the normalized mixture spectrum and pure spectra 
provide better accuracy than PLS with a mixture of glucose, of ethanol and its metabolites, acetaldehyde and acetate, 
lactic acid, and creatinine ranging in concentration from 0 to mixed in high equimolar quantities SO the spectral features 
66 mM. See Berger et al., An enhanced algorithm for  linear and relative Raman cross section of each could be easily 
multivariate calibration, Anal. Chem. 1998; 70: 623-627, the 55 compared (measured concentration versus actual concentra- 
contents of which are hereby incorporated by reference as if tion of % ethanol). FIG. 33 is a graph of PLS-measured 
recited in full herein. PLS and HLA were used to predict ethanol concentration plotted with respect to actual ethanol 
glucose levels in whole blood and serum with reasonable concentration in aqueous solution. 
success with a standard error of prediction (SEP)=21 mg/dL FIG. 34 illustrates the Raman spectra for 0.333M aqueous 
for PLS and SEP=17 mgidL for HLA. See Berger et al., 60 solutions of ethanol, acetaldehyde, acetic acid, and mixed 
Multi-component Blood Analysis by Near-Infrared Raman metabolites across a range of wave numbers between 700- 
Spectroscopy, Applied Optics, 1999: 38: 2916-2926, the con- 1700 withamplitude inarbitrary units. FIG. 34 shows that the 
tents of which are hereby incorporated by reference as if Raman spectra for 0.333M aqueous solutions of ethanol, 
recited in full herein. acetaldehyde, and acetic acid each have similar Raman cross- 
PLS andor HLA can be used as linear models to solve for 65 sections. The spectrum of amixture ofthe three metabolites is 
the concentration of ethanol in a selected region in the eye, a sum of the individual spectra, demonstrating adherence to 
such as in the aqueous humor. Both PLS and HLA calibration the Beer-Lambert law. 
Each 
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Mathematical addition of the spectra of the pure constitu- 
ents results in a curve that is virtually identical to the mea- 
sured spectra of the mixed sample. Therefore, the mixture of 
these constituents obeys the Beer-Lambert law in aqueous 
solution. Thus, as contemplated by embodiments of the 
present invention, PLS and/or HLA models can measure the 
concentrations of ethanol and/or its metabolites in the spec- 
tral sample from a signal of mixed constituents (to determine 
blood and/or brain (or cerebral spinal fluid) concentration). 
FIG. 35 is a block diagram of exemplary embodiments of 
data processing systems that illustrates systems, methods, 
and computer program products in accordance with embodi- 
ments of the present invention. The processor 310 communi- 
cates with the memory 314 via an addressidata bus 348. The 
processor 310 can be any commercially available or custom 
microprocessor. The memory 314 is representative of the 
overall hierarchy of memory devices containing the software 
and data used to implement the functionality of a data pro- 
cessing system 305. The memory 314 can include, but is not 
limited to, the following types of devices: cache, ROM, 
PROM, EPROM, EEPROM, flash memory, SRAM, and 
DRAM. 
As shown in FIG. 35, the memory 314 may include several 
categories of software and data used in the data processing 
system: the operating system 352; the application programs 
354; the inputioutput (IiO) device drivers 358; module of a 
Raman spectral analyzer configured to analyze at least one 
selected analyte of interest in the blood and/or brain (brain 
level) by evaluating the spectra of a selected region in the eye 
350; and the data 356. The data 356 can include reference 
Raman spectrum signal data of the selected analyte(s) at a 
variety of concentrations as well as the Raman spectrum data 
being interrogated 362 which may be obtained in substan- 
tially real-time from a Raman spectrometer or signal acqui- 
sition system 320. As will be appreciated by those of skill in 
the art, the operating system 352 may be any operating system 
suitable for use with a data processing system. 
The IiO device drivers 358 typically include software rou- 
tines accessed through the operating system 352 by the appli- 
cation programs 354 to communicate with devices such as IiO 
data port(s), data storage 356 and certain memory 314 com- 
ponents and/or the image acquisition system 320. The appli- 
cation programs 354 are illustrative of the programs that 
implement the various features of the data processing system 
and preferably include at least one application that supports 
operations according to embodiments of the present inven- 
tion. Finally, the data 356 represents the static and dynamic 
data used by the application programs 354, the operating 
system 352, the IiO device drivers 358, and other software 
programs that may reside in the memory 314. 
While the present invention is illustrated, for example, with 
reference to the Raman spectral anaylzer module 350 being 
an application program in FIG. 35, as will be appreciated by 
those of skill in the art, other configurations may also be 
utilized while still benefiting from the teachings of the present 
invention. For example, the module 350 may also be incor- 
porated into the operating system 352, the IiO device drivers 
358 or other such logical division of the data processing 
system 305. Thus, the present invention should not be con- 
strued as limited to the configuration of FIG. 35, which is 
intended to encompass any configuration capable of carrying 
out the operations described herein. 
In certain embodiments, the module 350 includes com- 
puter program code for confirming the presence of and/or 
quantifying the concentration of at least one selected analyte 
of interest based on a statistical model that identifies certain 
particular wave numbers of interest. The module 350 may 
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comprise at least one of: (a) partial least squares model; and 
(b) a hybridized linear model of the Raman spectra of the 
analyte of interest. The statistical model can be configured so 
that the module 350 evaluates a subset of the wave numbers 
5 (of pre-selected wave numbers) chosen so that they provide 
sufficient data about the amount of analyte present in the 
sample without requiring sampling of the entire wave number 
spectrum. In particular embodiments, the wave numbers can 
be in the range of between about 700-1700 cm-'. 
The module 350 can be configured to detect chemical 
signatures, or quantify levels in the blood and/or brain of 
selected analytes, including, but not limited to, ethanol and/or 
its metabolites, glucose, or other desired analyte. In particular 
embodiments, the module 350 includes a mathematical 
15 model for obtaining spectra and analyzing the spectra to 
determine the concentration (blood and/or brain) of ethanol, 
acetaldehyde, and acetic acid. The model may analyze a 
plurality of predetermined narrow (less than about 200 cm-', 
and typically less than about 100 cm-') segments in the 
20 Raman signal (selectively excluding regions that may shift 
due to increase or decrease in vivo concentration). The mod- 
ule 350 can include computer program code that can normal- 
ize the data by dividing the spectra of the ethanol, acetalde- 
hyde and acetic acid by the area under the curve of a selected 
25 portion of the spectrum. In certain embodiments, the normal- 
ization is carried out using spectra data associated with the 
hydrogen-bonding region in the 400-600 cm-' range of the 
collected Raman response signal. The module 350 can also 
include computer program code for evaluating the retina or 
30 iris for identity purposes as discussed above (the identifica- 
tion program code and equipment may be also held in a 
separate module). 
The dataiprocessor structure or devices shown and 
described with respect to FIG. 35 may also be used to imple- 
35 ment other computer program products to carry out certain 
operations of any of the embodiments described herein. 
An IiO data port can be used to transfer information 
between the data processing system 310 and the Raman spec- 
4o trometer or signal acquisition system 320 or another com- 
puter system or a network (e.g., the Internet) or to other 
devices controlled by the processor. The computer program 
code with the module 350 may be held in a device proximate 
the spectrometer 320 or remotely. For remote configurations, 
45 the signal data may be wirelessly relayed for evaluation. 
These components may be conventional components such as 
those used in many conventional data processing systems, 
which may be configured in accordance with the present 
invention to operate as described herein. 
While the present inventionis illustrated, for example, with 
reference to particular divisions of programs, functions and 
memories, the present invention should not be construed as 
limited to such logical divisions. Thus, the present invention 
shouldnot be construedas limited to the configuration of FIG. 
55 35 but is intended to encompass any configuration capable of 
carrying out the operations described herein. 
The flowcharts and block diagrams of certain of the figures 
herein illustrate the architecture, functionality, and operation 
of possible implementations of probe cell estimation means 
60 according to the present invention. In this regard, each block 
in the flow charts or block diagrams represents a module, 
segment, or portion of code, which comprises one or more 
executable instructions for implementing the specified logi- 
cal function(s). It should also be noted that in some alternative 
6 5  implementations, the functions noted in the blocks may occur 
out of the order noted in the figures. For example, two blocks 
shown in succession may in fact be executed substantially 
10 
50 
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concurrently or the blocks may sometimes be executed in the in vivo Raman spectrum of the aqueous humor of the subject 
reverse order, depending upon the functionality involved. and comparing the first and second Raman spectrums to per- 
In summary, embodiments of the present invention are form at least one of: (a) detecting an alteration in the function 
directed to intermittent, semi-continuous, or continuous of the blood brain baffler; (b) identifying the presence or 
monitoring of systemic levels of analytes of interest, such as 5 absence of a selected substance in the brain or cerebral spinal 
ethanol and its metabolites, with Raman spectroscopy. This fluid: and (c) determining a brain or cerebral spinal fluid 
can be with techniques that are non-invasive or minimally concentration level of a selected substance. 
invasive. In addition, the devices used to carry out the inter- 5. A method according to claim 1 wherein the Raman 
rogation of the biosample (Le, AH) can be miniaturized for spectrum is obtained without physically contacting the eye of 
portability. These devices can have the capability ofreal-time i o  the subject. 
data recording and telemetry for communication with inte- 6. A method of non-invasively detecting the presence or 
grated data analysis systems. Such systems, with remote data absence of an analyte in the cerebral spinal fluid or brain 
analysis, can allow research on human behavior, physiology, andor monitoring the blood brain baffler of a subject, com- 
evaluation of the efficacy of drug and social therapies with prising the steps of: 
regard to inhibiting or preventing alcohol consumption and 15 generating an excitation beam at a wavelength of between 
the like. about 400 to 900 nanometers; 
The foregoing is illustrative of the present invention and is focusing the excitation beam of said generating step into 
not to be construed as limiting thereof. Although a few exem- the eye of the subject so that a selected region is illumi- 
plary embodiments of this invention have been described, nated; 
those skilled in the art will readily appreciate that many 20 obtaining a Raman spectrum corresponding to the illumi- 
modifications are possible in the exemplary embodiments nated region; and 
without materially departing from the novel teachings and detecting the presence or absence of an analyte in the brain 
advantages of this invention. Accordingly, all such modifica- or cerebral spinal fluid andor monitoring the blood 
tions are intended to be included within the scope of this brain baffler dynamics based on said detecting step, 
invention as defined in the claims. In the claims, means-plus- 25 wherein said detecting step comprises assessing whether 
function clauses, where used, are intended to cover the struc- the dynamics of the blood brain baffler allow at least one 
tures described herein as performing the recited function and selected analyte, which would normally be inhibited 
not only structural equivalents but also equivalent structures. from traveling through the blood brain barrier, to pass 
Therefore, it is to be understood that the foregoing is illustra- into the intracranial spinal fluid through the blood brain 
tive of the present invention and is not to be construed as 30 barrier. 
limited to the specific embodiments disclosed, and that modi- 7. A method according to claim 6, wherein said method 
fications to the disclosed embodiments, as well as other further comprises the steps of: administering a non-specific 
embodiments, are intended to be included within the scope of marker to the subject, the non-specific marker being selected 
the appended claims. for its normal reluctance to pass through the blood brain 
The statements characterizing one or more of the priority 35 barrier; comparing the Raman spectrum from said obtaining 
applications as a “continuation-in-part’’ application of a prior step to predetermined reference spectra corresponding to the 
application listed under the “Related Applications” section non-specific marker; and identifying the presence of the non- 
above indicate that additional subject matter was added to the specific marker in the obtained Raman spectrum thereby indi- 
specification of the prior application, but does not necessarily cating that the dynamics of the blood brain barrier have 
indicate that the entire invention described and claimed 40 changed. 
herein is not supported in full by the prior application(s). The 8. A method according to claim 7, further comprising the 
invention is defined by the following claims, with equivalents step of introducing a cytotoxic agent to the subject after said 
of the claims to be included therein. identifying step. 
We claim: 9. A method of non-invasively detecting the presence or 
1. A method of non-invasively detecting the presence or 45 absence of an analyte in the cerebral spinal fluid or brain 
andor monitoring the blood brain barrier of a subject, com- 
prising the steps of: 
generating an excitation beam at a wavelength of between 
about 400 to 900 nanometers; 
focusing the excitation beam of said generating step into 
the eye of the subject so that a selected region is illumi- 
nated; obtaining a Raman spectrum corresponding to the 
illuminated region; and 
detecting the presence or absence of an analyte in the brain 
or cerebral spinal fluid and monitoring the blood brain 
baffler dynamics based on said detecting step, wherein 
said detecting step is carried out when the subject is 
exposed to elevated ambient pressures. 
10. A method of non-invasively detecting the presence or 
step is carried out by illuminating the aqueous humor of the 60 absence of an analyte in the cerebral spinal fluid or brain 
eye. andor monitoring the blood brain barrier of a subject, com- 
3. A method according to claim 1, wherein said detecting prising the steps of: 
step is carried out by illuminating the vitreous humor of the generating an excitation beam at a wavelength of between 
eye. about 400 to 900 nanometers; 
focusing the excitation beam of said generating step into 
step is carried out by obtaining a first invivo Raman spectrum the eye of the subject so that a selected region is illumi- 
of the aqueous humor of the subject then obtaining a second nated; 
absence of an analyte in the cerebral spinal fluid or brain 
andor monitoring the blood brain barrier of a subject com- 
prising the steps of: 
generating an excitation bean at a wavelength of between 
about 400 to 900 nanometers; 
focusing the excitation bean of said generating step into the 
eye of the subject so that a selectedregion is illuminated; 
obtaining a Raman spectrum corresponding to the illumi- 
nated region; and 
detecting the presence or absence of an analyte in the brain 55 
or cerebral spinal fluid and monitoring the blood brain 
baffler dynamics based on said detecting step when the 
subject is exposed to gravity deficient environments. 
2. A method according to claim 1, wherein said detecting 
50 
4. A method according to claim 1, wherein said detecting 6 5  
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obtaining a Raman spectrum corresponding to the illumi- 
nated region; and 
detecting the presence or absence of an analyte in the brain 
or cerebral spinal fluid and monitoring the blood brain 
baffler dynamics based on said detecting step, wherein 5 
said method is carried out when the brain of the subject 
has been exposed to a trauma injury to determine 
whether there is an alteration of the dynamics of the 
blood brain baffler. 
selected analyte, which would normally be inhibited 
from traveling through the blood brain barrier, to pass 
into the intracranial spinal fluid through the blood brain 
barrier. 
13. A computer program product according to claim 12, 
further comprising computer program code configured to 
compare the Raman spectral response to a priori data using a 
hybrid linear analysis technique, 
14. A computer program product according to claim 12, 
11. A method according to claim 10, wherein said method i o  further comprising computer program code configured to 
drug on the dynamics of the blood brain baffler of the subject. 
12. A computer program product for monitoring the blood 
brain barrier and/or determining the presence and/or quantity 12, 
having computer one or more peaks of interest in the Raman spectral response 
readable program code embodied in said medium, said to identify the presence andor quantity of the substance in the 
subject. computer-readable program code comprising: 
computer readable program code configured to analyze a 16. A computer Program Product according to claim 15, 
Raman spectral response of a selected region of the eye 20 wherein the computer Program Product is configured to ana- 
of a subject to monitor the blood brain barrier andor lyze a chemical shift peak associated with a carbon-carbon 
determine the presence andor quantity of a selected double bond on the molecular structure of the analyte of 
in the intracranial andor cerebral spinal fluid interest to identify tile concentration of the substance in the 
of a subject; and subject. 
is carried Out during drug to the impact Of the compare the Raman spectral response to a priori data using a 
partial least squares technique, 
15. A computer program product according to 
ofa  selected substance in the brain ofa  subject, comprising: 15 wherein the program ‘Ode is ‘Onfigured to a 
a computer readable storage 
computer program code configured to assess whether the 25 
dynamics of the blood brain barrier allow at least one * * * * *  
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 7,398,119 B2 
APPLICATION NO. : 10/396035 
DATED : July 8,2008 
INVENTOR( S) : Lambert et al. 
Page 1 of 2 
It is certified that error appears in the above-identified patent and that said Letters Patent is 
hereby corrected as shown below: 
Column 53, Claim 
Column 53, Claim 
Column 53. Claim 
, Line 5 1 : Please correct “focusing the excitation bean” 
To read -- focusing the excitation beam -- 
, Line 56: Please correct “spinal fluid and monitoring” 
To read -- spinal fluid and/or monitoring -- 
, Line 57: Please correct “baffler dynamics” 
To read -- barrier dynamics -- 
Column 54, Claim 4, Line 4: Please correct “of the blood brain baffler” 
To read -- of the blood brain barrier -- 
Column 54, Claim 6, Line 13: Please correct “the blood brain baffler” 
To read -- the blood brain barrier -- 
Column 54, Claim 6, Line 24: Please correct “brain baffler” 
To read -- brain barrier -- 
Column 54, Claim 6, Line 26: Please correct “of the blood brain baffler” 
To read -- of the blood brain barrier -- 
Column 54, Claim 9, Line 56: Please correct “baffler dynamics” 
To read -- barrier dynamics -- 
Column 55, Claim 10, Line 5:  Please correct “baffler dynamics” 
To read -- barrier dynamics -- 
Column 55, Claim 10, Line 9: Please correct “blood brain baffler” 
To read -- blood brain barrier -- 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 7,398,119 B2 
APPLICATION NO. : 10/396035 
DATED : July 8,2008 
INVENTOR( S) : Lambert et al. 
Page 2 of 2 
It is certified that error appears in the above-identified patent and that said Letters Patent is 
hereby corrected as shown below: 
Column 55, Claim 11, Line 12: Please correct “of the blood brain baffler” 
To read -- of the blood brain barrier -- 
Signed and Sealed this 
Thirtieth Day of September, 2008 
JON W. DUDAS 
Director of the United States Patent and Trademark Ofice 
